

Index

- Acanthosis nigricans, 441
 Acute enteritis
 infectious, 293–6
 non-infectious, 295–8
 Acute gastritis, 187
 acute erosive, haemorrhagic,
 or stress gastritis, 187
 Acute graft-versus-host disease
 (GvHD)
 apoptosis and, 59
 diagnosis, 59
 histological features, 57–9, 60
 histological grading system, 59
 as mimic of inflammatory
 bowel disease (IBD),
 369–70, 372
 Acute ischaemia, intestine, 85–6,
 89
 Acute oesophageal necrosis
 (AEN), 84–5
 endoscopic features, 84
 general features, 84
 histological features, 84
 macroscopic features, 84
 risk factors, 84
 Acute severe colitis, biopsies and,
 10
 Adenocarcinoma
 colorectal, in inflammatory
 bowel disease (IBD), 397
 precursors of, 122–4
 risk factors for, 397
 gastric, precursors of, 121
 in ileal pouch anal
 anastomosis, 415
 in immunosuppression, 55
 mimics of
 inflammatory cloacogenic
 polyps, 428
 mucosal prolapse, 428
 prolapse at stomas, 428
 related to prolapse, 428
 oesophageal, precursors of,
 159
 small intestine, 303–4
 precursors of, 225–6
 Adenovirus
 clinical features, 260–2
 general features, 260–2
 histology, 53, 260–2, 294, 295
 immunosuppression and, 53
 in lower GI tract
 differential diagnosis, 261
 practical considerations,
 261
 AEN. *See* Acute oesophageal
 necrosis (AEN)
 AIDS. *See* Human immunodeficiency
 virus (HIV)
 AIE (Autoimmune enteropathy),
 227–30
 as mimic of inflammatory
 bowel disease (IBD), 373
 Allergic colitis/enterocolitis,
 103–4
 Allergic conditions in children
 allergic colitis/enterocolitis,
 103–4
 causes, 103
 diagnosis, 103–4
 histological features, 104
 prevalence of, 103
 eosinophilic gastroenteritis
 (EGE), 104–5
 diagnosis, 105
 pathogenesis, 105
 prevalence of, 104–5
 symptoms of, 105
 overview, 103
 Allergic gastritis. *See*
 Eosinophilic (allergic)
 gastritis
 Aluminum, drug-induced
 disease of stomach and,
 67
 Amoebiasis, intestinal
 as complication of
 inflammatory bowel
 disease (IBD), 392–4
 histological features, 278, 368,
 392–4
 as mimic of inflammatory
 bowel disease (IBD),
 364–8
 Amyloidosis, 15–18
 associated diseases, 16
 clinical features, 15–16
 course and treatment, 17
 diagnosis, 16–18
 differential diagnosis, 16–17
 epidemiology, 15
 GI tract involvement, 16, 18
 histopathology, 16–18
 liver involvement, 16
 major protein components, 16
 as mimic of collagenous colitis,
 319
 summary of condition, 15
 Anal diseases
 abscesses, 436
 causes, 436
 acanthosis nigricans, 441
 anal intraepithelial neoplasia
 (AIN), 125–6
 LAST classification system,
 128
 relationship with human
 papillomavirus (HPV)
 infection and, 442
 value of p16 immuno-
 histochemistry for
 diagnosis, 128
 anatomy of anal canal, 434
 bullous lesions, 442–3
 Chlamydia trachomatis
 (lymphogranuloma
 venereum), 439
 common conditions, 434
 Crohn's disease, 437–8
 hidradenitis suppurativa
 compared, 438
 duplication, 442–3
 dysplasia
 p16 immunochemistry,
 value of, 128
 terminology, 125–6, 127,
 128
 eczema, 440–1
 fissures, 434–5
 causes, 435
 in Crohn's disease, 435
 general features, 434–5
 human immunodeficiency
 virus (HIV) and, 435
 indications for biopsy, 435
 fistulas, 436–7
 causes, 437
 histology, 437
 haemorrhoids, 434–5
 contents of report, 435
 possible incidental changes,
 435
 types of specimen, 435
 Herpes simplex virus (HSV),
 439
 hidradenitis suppurativa, 438
 anal Crohn's disease
 compared, 438
 human immunodeficiency
 virus (HIV) and, 438–9
 aetiologies of HIV-
 associated lesions, 438
 HIV-associated lesions, 439
 incidental lesions, 439
 human papilloma virus (HPV)
 and, 442
 iatrogenic anal diseases
 oleogranulomas, 444
 pouch surgery, 444
 radiation damage and, 444
 inflammatory cloacogenic
 polyps, 441–2
 intraepithelial neoplasia (*See*
 Anal intraepithelial neo-
 plasia (AIN))
 lichen planus, 441
 lichen sclerosus, 441
 molluscum contagiosum,
 439–40
 mucosal prolapse, 441–2
 oleogranulomas, 444
 pilonidal sinus, 443–4
 differential diagnosis,
 444
 histology, 443–4
 psoriasis, 441
 radiation damage, 444
 syphilis, 440
 histological features,
 440
 incidence, 440
 lesions, 440
 practical considerations,
 440
 tags, 435–6
 causes, 436
 granulomas and, 436
 histological features, 436
 Anal intraepithelial neoplasia
 (AIN), 125–6
 LAST classification system,
 128
 relationship with human
 papillomavirus (HPV)
 infection and, 442
 value of p16 immuno-
 histochemistry for
 diagnosis, 128

- Ancylostoma duodenale (hookworm)
clinical features, 280
differential diagnosis, 280
macroscopic pathology, 280
microscopic pathology, 280
- Angiodysplasia, 90–1
- Anus
anal diseases (*See* Anal diseases)
anatomy of, 434
drug-induced disease, 78
dysplasia of
p 16 immunochemistry, value of, 128
terminology, 125–6, 127, 128
radiation damage, 444
- Apoptosis
acute graft-versus-host disease (GvHD) and, 59
inflammatory bowel disease (IBD) and, 347–8
normal large intestinal mucosa and, 256
- Apoptotic enteropathy, drugs and, 68, 69
- Appendix
diverticula, 417–18
radiation damage, 43
- Arteriovenous malformation (AVM), 94, 95
- Ascaris lumbricoides (roundworm), 280
- Aspergillus, 275
differential diagnosis of filamentous fungi, 276
lower GI tract, 275
oesophagus, 172
- Atrophic autoimmune pangastritis, 194
- Atrophic gastritis, 186–7
- Autoimmune enteropathy (AIE), 227–30, 373
as mimic of coeliac disease (CD), 227–30
as mimic of inflammatory bowel disease (IBD), 373
- Autoimmune gastritis, 192–4
- AVM (Arteriovenous malformation), 94, 95
- “Backwash” ileitis, 341–3
- Bacterial infections. *See also specific infection*
bacterial enteritis, 294–6
bacterial oesophagitis, 171–2
actinomycosis, 172
bartonella, 171–2
other bacterial infections, 172
role of bacteria, 171
role of bacteria in infective oesophagitis, 171
syphilis, 171–2
tuberculosis (TB), 171–2
campylobacter, 263–4
Chlamydia trachomatis (lymphogranuloma venereum), 273–5, 439
clinical features, 275
human immunodeficiency virus (HIV) and, 52, 362–4, 439
microscopic pathology, 275
as mimic of inflammatory bowel disease (IBD), 362–4
- Clostridioides difficile
clinical features, 270–1
as complication of inflammatory bowel disease (IBD), 394
differential diagnosis, 271
pathology, 271
- Clostridium perfringens, 270
- Clostridium septicum, 270
as complication of inflammatory bowel disease (IBD), 394
Campylobacter jejuni, 394
Clostridium difficile, 394
tuberculosis (TB), 394
- Escherichia coli (E. coli), 268–9
clinical features, 270
differential diagnosis, 268
general features, 268–9
macroscopic pathology, 270
microscopic pathology, 270
symptoms of, 268–9
- gonorrhoea, 275
proctitis, 275
immunosuppression and, 52
injury patterns as guide to cause of enterocolitis, 263
- Klebsiella oxytoca, 268–70
differential diagnosis, 270
in lower GI tract, 263–75 (*See also specific infection*)
- lymphogranuloma venereum (Chlamydia trachomatis), 273–5, 439
clinical features, 275
human immunodeficiency virus (HIV) and, 52, 362–4, 439
microscopic pathology, 275
as mimic of inflammatory bowel disease (IBD), 362–4
- mycobacterial diseases (*See* Mycobacterial diseases)
- pathological features, patterns of, 264
- salmonella
clinical features, 267
macroscopic pathology, 267
microscopic pathology, 267
non-typhoid salmonella enterica, 266
differential diagnosis, 266
salmonella typhi (typhoid fever), 265–6
differential diagnosis, 266
sexually transmitted bacterial proctocolitides, 275
- Chlamydia trachomatis (lymphogranuloma venereum), 273–5, 439
clinical features, summary, 275
gonorrhoeal proctitis, 275
microscopic pathology, summary, 275
- Herpes simplex virus (HSV), 261–2
- lymphogranuloma venereum (Chlamydia trachomatis), 273–5, 439
macroscopic pathology, summary, 275
microscopic pathology, summary, 275
organisms, 275
syphilis (*See* Syphilis)
- shigellosis, 266–8
clinical features, 266–8
differential diagnosis, 267
general features, 266–8
macroscopic pathology, 267
microscopic pathology, 267
- spirochaetes (*See* Spirochaetes)
- syphilis
differential diagnosis, 273
general features, 272–4
practical considerations, 273
tuberculosis (*See* Tuberculosis (TB))
- Vibrio cholerae, 263
- yersiniosis, 264–5
clinical features, 265
differential diagnosis, 265
macroscopic features, 265
microscopic features, 265
as mimic of inflammatory bowel disease (IBD), 364
- Barrett’s oesophagus (BE/BO)
biopsy protocols, 2–3, 4
cardia intestinal metaplasia distinguished, 164
clinical definition, 2–3
clinical features, 2–3
dysplasia in
high grade dysplasia (HGD), 163
histology, 161
indefinite for dysplasia (IFD), 162
low grade dysplasia (LGD), 162
negative for dysplasia, 161–2
pathology report contents, 163
goblet cells, 163
histological features, 159–161
pathology report contents, 163
prevalence of, 159, 166
- Basal giant cells, diagnosis of inflammatory bowel disease (IBD) and, 332
- Basal lymphoid aggregates, diagnosis of inflammatory bowel disease (IBD) and, 332
- Basal plasmacytosis, diagnosis of inflammatory bowel disease (IBD) and, 329–39
- Basidiobolomycosis, 276–7
differential diagnosis, 276
- BE. *See* Barrett’s oesophagus (BE/BO)
- Behçet’s disease, 26–7, 97–8, 366–9
clinical features, 26
Crohn’s disease, features resembling, 369
diagnosis, 26
differential diagnosis, 26
epidemiology, 26
GI tract involvement, 26, 366–9
histology, 26, 366–9
as mimic of inflammatory bowel disease (IBD), 366–9
histological features that may distinguish, 369
- Biologic agents, drug-induced disease of large intestine and, 77
- Biopsies of GI tract
anal fissures and, 435
Barrett’s oesophagus, biopsy protocol, 2–3, 4
clinical relevance, 1–2
clinician’s requirements, 2
macroscopic disease, 1, 2
microscopic disease, 1, 2
reassurance, 1–2
colonic (*See* Large intestine)
- duodenal
approach to sampling, 6, 8
coeliac disease (CD), 7, 8
duodenal ulceration or strictures, 8
general points, 8
duodenitis and, 206
endometriosis and, 429
gastric
approach to biopsy sampling, 5
gastric atrophy, 5–6, 7
gastric polyps, 5, 7
gastric ulcer, 5, 7
gastritis, 6
Helicobacter pylori gastritis, 5, 7, 194
histological approach, 182–3
checklist, 183
indications for, 7, 179
iron deficiency anemia (IDA), 6, 7

Index

- Biopsies of GI tract (cont.)
 gastroenterologist's requirements from
 histopathology report, 2
 gastro-oesophageal reflux disease (GORD) and, 3, 4
 Helicobacter pylori gastritis and, 5
 ancillary methods of
 detecting in, 195
 indications, 7
 histology report, 183
 body of, 184
 conclusion, 184
 structure of, 184
 historical background, 1
 ileal pouch anal anastomosis (IPAA), types of biopsies, 9, 10, 411
 ileal/terminal ileal/jejunal focal and stenosing lesions, 303
 indications for biopsy, 10
 value of, 8, 289–90, 306
 immunochemistry, 179
 indications, 2
 inflammatory bowel disease (IBD) and, 9, 10
 in children, 106–7
 colorectal cancer surveillance, approach, 10
 features favouring IBD over other causes, 340
 histological mimics of, 384
 new diagnosis, 9, 10
 surveillance for colorectal carcinoma (CRC), 9, 10
 laboratory processing and staining, 179
 large intestinal
 acute severe colitis, 10
 colorectal carcinoma (CRC) and colorectal polyps, 9–10
 colorectal neoplasia, 10
 in IBD, 10
 graft-versus-host disease (GvHD), 10
 indications, 10
 inflammatory bowel disease (IBD), 9, 10
 microscopic colitis, 8–9, 10
 pouchitis, 10
 oesophageal
 Barrett's oesophagus (BE), biopsy protocol, 2–3, 4
 benign strictures, 3–4
 eosinophilic oesophagitis (EO)
 biopsy protocol, 3, 4
 features, 173–4, 175
 gastro-oesophageal reflux disease (GORD), 3, 4
 general points, 4
 indications, 4
 miscellaneous conditions, 4
 oesophageal ulceration, 3, 4
 tissue sampling, 2
 pouch (See Ileal pouch anal anastomosis (IPAA))
 reporting of (See Reporting inflammatory bowel disease (IBD))
 special stains, 179
 transplantation, 57–61
 clinical data needed for
 optimal assessment, 62
 Bisphosphonates, drug-induced disease of oesophagus and, 66
 Blastocystis hominis as complication of inflammatory bowel disease (IBD), 394
 BO. See Barrett's oesophagus (BE/BO)
 Bone marrow transplantations and GI tract, 60
 Brunner's glands, 153–4
 Bullous skin lesions
 anal region, 442–3
 dermatitis herpetiformis and coeliac disease (CD), 442–3
 C. difficile. See Clostridioides difficile
 Campylobacter, 263–4
 as complication of inflammatory bowel disease (IBD), 394
 Candida
 gastric, 198
 in ileal pouch anastomosis, 411
 oesophageal, 172
 in oesophageal radiation damage, 39
 small intestinal, 295
 Chagas disease, 278
 Checkpoint inhibitor colitis as mimic of inflammatory bowel disease (IBD), 376
 Chemotherapy
 colitis and
 as mimic of inflammatory bowel disease (IBD), 376
 neutropaenic enterocolitis, 61, 270
 gastritis and, 66, 68, 200–1
 atypia in, 68
 radiation damage distinguished, 31
 Children. See Paediatric conditions
 Chlamydia trachomatis (lymphogranuloma venereum), 273–5, 362–4, 439
 clinical features, summary, 275
 human immunodeficiency virus (HIV) and, 52, 362–4, 439
 microscopic pathology, 275
 as mimic of inflammatory bowel disease (IBD), 362–4
 Cholera, 263
 Cholestyramine, drug-induced disease of large intestine and, 74–5
 Chronic graft-versus-host disease (GvHD), 59–60
 as mimic of inflammatory bowel disease (IBD), 370, 372–3
 Chronic granulomatous disease, 61
 as mimic of inflammatory bowel disease (IBD), 377–8
 Chronic ileitis
 causes, 297–302, 298
 clues to cause, 298
 histological features suggesting chronicity in, 293
 Chronic infective diarrhoea
 bacterial causes, 294
 definition of, 294
 viral causes, 294
 Chronic mesenteric ischaemia, 85–6, 89
 Clostridioides difficile
 clinical features, 271
 as complication of inflammatory bowel disease (IBD), 394
 differential diagnosis, 271
 macroscopic pathology, 271
 microscopic pathology, 271
 symptoms of, 270
 Clostridium perfringens, 270
 Clostridium septicum, 270
 CMV. See Cytomegalovirus (CMV)
 Coeliac disease (CD)
 biopsies and, 7, 8, 223
 classification of, 220–1
 clinical features, 7
 collagenous sprue (CS), 219–20
 complications, 221–4
 enteropathy-associated T-cell lymphoma (EATL), 223–5
 other malignancies, 225–6
 RCD 1, 221–2
 RCD 2, 222–3
 refractory CD (RCD), 221
 summary, 221–4
 ulcerative jejunitis (UJ), 223
 dermatitis herpetiformis and, 24–5
 diagnosis
 genetic testing, 215
 histopathology, 215–19
 serological testing, 215
 differential diagnosis
 autoimmune enteropathy (AIE), 227–30
 common variable immunodeficiency (CVID), 230
 Crohn's disease, 232
 mimics, 8
 peptic duodenitis, 231
 small intestinal bacterial overgrowth (SIBO), 230
 summary, 226–9
 tropical sprue (TS), 230–1
 duodenitis distinguished, 208, 231
 epidemiology, 215
 histological features, 216
 intraepithelial lymphocytes, 208–9, 226–9
 causes of increase in, summary, 219
 other parts of GI tract involvement, 220
 peptic duodenitis (PD) distinguished, 208, 231
 summary, 232
 symptoms of, 215
 treatment, 215
 Colchicine, stomach and, 67
 Colitis. See specific type of colitis
 Collagen band, 187, 219–20, 254
 Collagenous colitis
 differential diagnosis, 318–19
 lymphocytic colitis distinguished, 320
 pathological features, 311–12
 Collagenous gastritis, 187
 Collagenous sprue (CS), 219–20
 Colon. See Large intestine
 Colorectal carcinoma (CRC)
 biopsies and, 10
 inflammatory bowel disease (IBD), surveillance for colorectal cancer, 9, 10
 sampling at endoscopy, 9–10
 as complication of inflammatory bowel disease (IBD)
 characteristic features, 397
 pathology, 397
 risk factors, 397
 Colorectal dysplasia
 in inflammatory bowel disease (IBD), 125
 in serrated lesions, terminology of, 124
 sporadic colorectal dysplasia, 122–4
 Colorectal polyps
 biopsies and, 9–10
 in inflammatory bowel disease (IBD), 398
 serrated lesions, 125
 histological features, 123
 terminology, 124
 Columnar dysplasia
 diagnosis, 116–17
 microscopic features, 118

- Common variable immunodeficiency (CVID), 61, 230, 376–7
- coeliac disease (CD)
 distinguished, 230
- colorectal histology, 377
- giardiasis, association with, 210
- immunosuppression and, 61
- as mimic of inflammatory bowel disease (IBD), 376–7
- Cord colitis syndrome, 60
- CRC. *See* Colorectal carcinoma (CRC)
- Crohn's disease
 anal Crohn's disease, 437–8
 hidradenitis suppurativa compared, 438
- anal fissures in, 435
- Behçet's disease features resembling, 369
- clinical features, 326–7
- coeliac disease (CD)
 distinguished, 232
- differential diagnoses of ileitis, 9
- diversion proctocolitis (DPC), 361
- diverticular disease and, 424–5
- features favouring Crohn's disease over UC, 346
- absence of UC features, 343
- contour of mucosal surface, 344
- disproportionate submucosal inflammation, 344–5
- focality of acute inflammation, 344–6
- focal or segmental changes, 341, 345
- gradient of changes between sites, 344
- granulomas, 341
- ileal involvement, 341–3
- non-diffuse (focal or patchy) chronic inflammation, 341
- reliable distinguishing features, 341–3, 344
- summary, 346
- fistulas in, 396
- ileal pouch anal anastomosis (IPAA) in, 412–15
- diagnosis, 415
- reasons for, 415
- ileitis in, 300
- early microscopic features, 300
- general considerations, 300
- pathological features, 300
- villous abnormalities, 300
- paediatric Crohn's disease, 108–10
- subclassification of inflammatory bowel disease (IBD) as, 347
- tuberculosis (TB) features resembling, 366
- upper GI tract involvement, 232, 236
- clinical features, 237
- frequency of selected histological features, 242
- value of involvement for distinguishing from UC, 237
- Cryoglobulinaemic vasculitis, 97–8
- Crypt atrophy, diagnosis of inflammatory bowel disease (IBD) and as feature of IBD, 331
- as feature of ulcerative colitis (UC), 337–43
- Crypt branching/crypt distortion, diagnosis of inflammatory bowel disease (IBD) and, 331
- Crypt dysplasia, 119–20
- Cryptolytic granulomas, 340, 341
- in diversion proctocolitis, 361
- in diverticular colitis, 357–9
- in GvHD, 59–60
- in inflammatory bowel disease (IBD), 345–7
- Cryptosporidium parvum, 278–9
- differential diagnosis, 279
- duodenitis and, 210, 278–9
- Crystal deposition
 large intestine, 74–5
- small intestine, 72
- Cuffitis, 412–13
- CVID. *See* Common variable immunodeficiency (CVID)
- Cytomegalovirus (CMV)
 biopsy reports and, 406
- as complication of inflammatory bowel disease (IBD)
 clinical features, 261
- diagnosis, 389–91
- histological features, 391
- prevalence in IBD of, 389
- underlying IBD in new patient with CMV, 391
- DNA real-time polymerase chain reaction, 392
- duodenitis and, 212
- gastritis and, 197
- histological features, 261, 391
- immunochemistry and, 392, 393
- interpretation of, 261, 393
- immunosuppression and, 53
- inclusions, 391, 392
- in lower GI tract, 260–1
- clinical features, 261
- differential diagnosis, 261
- macroscopic pathology, 261
- microscopic pathology, 261
- oesophagitis and, 170
- tests for, 391–2
- DNA real-time polymerase chain reaction, 392
- immunochemistry and, 392, 393
- Dasatinib, drug-induced disease of large intestine and, 76–7
- Dermatitis herpetiformis, 24–5
- Dermatological conditions, 24–6
- coeliac disease (CD) and, 24–5
- GI tract and, 25
- inflammatory bowel disease (IBD) and, 25
- liver and, 25
- oesophagus and, 25
- Dieulafoy's lesion, 93–4, 95
- Diversion proctocolitis (DPC), 358–62
- general features, 361
- histology
 on background of Crohn's disease, 361
- on background of non-IBD, 361
- on background of ulcerative colitis (UC), 361
- summary, 361
- unusual or potentially confusing histological features, 361
- as mimic of inflammatory bowel disease (IBD), 358–62
- Diverticular colitis
 generally, 430
- anatomical distribution, 424
- Crohn's disease and, 424–5
- endoscopic appearances, 422
- inflammatory bowel disease (IBD) and, 357–9, 424, 425
- macroscopic appearances, 422
- microscopic appearances, 357–9, 423, 424
- as mimic of inflammatory bowel disease (IBD), 357–9
- mucosal inflammation in, 423
- other types of colonic inflammation and, 425
- pathogenesis, 422
- prevalence of, 421
- terminology, 421
- ulcerative colitis (UC) and, 357–9, 421, 424
- Diverticulitis
 features of, 419–21
- mucosal inflammation in, 423
- Diverticulosis
 diverticular colitis as complication of (*See* Diverticular colitis)
- diverticulitis as complication of, 419–21
- general features, 417
- inflammatory bowel disease (IBD) and, 418, 424, 425
- inflammatory complications, 419–21
- macroscopic appearances, 418–19
- mucosal prolapse and, 418
- pathogenesis, 418–19
- prevalence of, 417
- Doxycycline, gastritis and, 200
- DPC. *See* Diversion proctocolitis (DPC)
- Drug-induced disease
 generally, 78
- anus, 78
- gastritis, 184, 199–200
- ileitis
 ipilimumab and, 71–2, 300
- mycophenolate mofetil (MMF) and, 56–7, 300
- non-steroidal anti-inflammatory drugs (NSAIDs) and, 300
- olmesartan and, 300
- large intestine, 72
- biologic agents and, 77
- cholestyramine, 74–5
- crystal deposition and, 74–5
- dasatinib, 76–7
- dysplasia, mimics, 74
- eosinophilic colitis pattern, 74
- focal active colitis pattern, 73
- hepatitis C treatment and, 77
- idelalisib, 76
- injury patterns, 73
- ipilimumab, 71–2, 376
- ischaemic colitis pattern, 73–4
- microscopic-type colitis, 74
- non-steroidal anti-inflammatory drugs (NSAIDs), 75–6
- PD-1 inhibitor gastroenterocolitis, 77–8
- pneumatosis coli/pneumatosis intestinalis, 75
- pseudomembranous colitis, 74
- rituximab, 77
- sevelamer, 74–5
- microscopic colitis, 74, 311
- mycophenolate mofetil (MMF)/mycophenolate (MPA), 69–70
- oesophagus
 bisphosphonates and, 66
- injury patterns, 65
- iron-pill associated disease (“pill oesophagitis”), 66
- sloughing oesophagitis, 65–6
- specific drugs, 66
- PD-1 inhibitor gastroenterocolitis, 77–8

Index

- Drug-induced disease (cont.)
small intestine, 68
apoptotic enteropathy, 69
crystal deposition and, 72
duodenal villous atrophy, 68–9
injury patterns, 68
intraepithelial
 lymphocytosis, 69
ipilimumab, 68, 71–2
kayexalate, 72
mycophenolate mofetil (MMF)/
 mycophenolate (MPA), 69–70
olmesartan, 68, 70–1, 300
stomach, 66
 aluminum-containing
 antacids or sucralfate, 67
 chemotherapy and, 68
 colchicine, 67
 injury patterns as result of
 medication, 66
 olmesartan, 200
 OsmoPrep, 67
 radiation and, 41, 67
 reactive/chemical
 gastropathy, 66–7
 ulceration, 67
 yttrium-90 microsphere
 selective internal
 radiation, 41, 67–8, 200–1
 upper GI tract, overview, 65
- Duodenal intraepithelial
 lymphocytosis, 69,
 208–9, 226–9
 causes of, summary, 219
- Duodenal mucosa, 147–50,
 287–9
 anatomy of duodenum, 147
 Brunner's glands, 153–4
 endocrine cells, 150
 epithelial cells, 151
 summary, 152
 fibroblasts, 150–1
 heterotopia, 153–4
 ileum and jejunum compared,
 249, 287–9
 inflammatory cells, 151–3
 intraepithelial lymphocytosis,
 69, 208–9, 226–9
 causes of, summary, 219
 lamina propria, 151, 153
 normal mucosa, 147–50, 152,
 153, 206
 submucosa, 153–4
 villous atrophy, medications
 and, 68–9
- Duodenal ulcer, 208
 biopsies and, 8
 clinical features, 6–7
 malignant duodenal ulcers or
 strictures, 8
- Duodenitis
 biopsies and, 206
- coeliac disease (CD)
 distinguished, 208
- Cryptosporidium parvum and,
 210
- duodenal tissue sampling, 206
- eosinophilic duodenitis, 209
- gastric metaplasia
 gastric heterotopia
 distinguished, 208
 general features, 208
 histology, 208
- general features, 208
- giardiasis and, 209–10
 histology, 209–10
 prevalence of, 209–10
 setting, 209–10
- histology, 208
- infectious causes
 cryptosporidium, 210
 giardiasis, 209–10
 microsporidiosis, 210
 strongyloidiasis, 210
 tuberculosis (TB), 212
 Whipple's disease, 210–12
- intraepithelial lymphocytosis
 and, 208–9, 226–9
 drug-induced, 69
- “lymphocytic duodenitis,”
 208–9
- microscopic enteritis and,
 208–9
- non-neoplastic lesions of
 heterotopic gastric mucosa,
 212
 heterotopic pancreas,
 212–13
 pseudomelanosis duodeni,
 213
- non-specific duodenitis, 206–7
- peptic duodenitis (PD), 206–7,
 231
 coeliac disease (CD)
 distinguished, 231
- peptic ulcer, 208
- strongyloidiasis and, 210
- tuberculosis (TB) and, 212
- viral duodenitis, 212
 cytomegalovirus (CMV)
 duodenitis, 212
 rotavirus, 212
- Whipple's disease and, 210–12
 general features, 212
 histology, 212
- Duodenum
 anatomy of, 147, 287
 biopsies of
 approach to sampling, 6, 8
 coeliac disease (CD), 7, 8
 duodenal ulcers or
 strictures, 7
 general points, 8
 heterotopia in
 gastric, 212
 pancreas, 212–13
 inflammatory bowel disease
 (IBD), 242–3
- mucosa (See Duodenal
 mucosa)
- villous atrophy, medications
 and, 68–9
- Dysplasia
 of anus
 p 16 immunochemistry,
 value of, 128
 terminology, 125–6, 127,
 128
 in Barrett's oesophagus (BE)
 high grade dysplasia
 (HGD), 163
 histology, 161
 indefinite for dysplasia
 (IFD), 162
 low grade dysplasia (LGD),
 162
 negative for dysplasia,
 161–2
 pathology reports, 163
- colorectal dysplasia
 in inflammatory bowel
 disease (IBD), 125,
 397–8
 biopsy reports and, 406
 in serrated lesions,
 terminology of, 124
- sporadic colorectal
 dysplasia, 122–4
- columnar dysplasia
 diagnosis, 116–17
 microscopic features,
 summary, 118
 non-neoplastic regenerative
 epithelial atypia
 distinguished, 118–20
- crypt dysplasia, 119–20
- definition, 116
- diagnosis
 generally, 116
 additional methods, 120–1
 challenges in, 118–21
 columnar dysplasia, 116–17
 crypt dysplasia, 119–20
 interobserver variability
 and, 120
 squamous dysplasia,
 117–19
- gastric epithelial dysplasia
 (GED)
 gastritis-associated
 dysplasia, 121–2
 general features, 121
 polypoid gastric dysplasia,
 122
 precursor lesions of invasive
 neoplasia, 121
 pyloric gland adenoma, 122
 rare types of, 122
- gastritis-associated dysplasia,
 121–2
- grading, summary, 121
- ileal pouch anal anastomosis
 (IPAA) and, 411, 414
- large intestine, as complication
 of inflammatory bowel
 disease (IBD), 397–8
- mimics, drug-induced disease
 of large intestine, 74
- regenerative columnar
 epithelial atypia
 distinguished, 118–20
 Riddell classification, 116
 squamous dysplasia, 117–19
 anal, 442
 oesophageal, 165–6
 summary, 127
 Vienna classification, 116
- E. coli.* See *Escherichia coli*
 (*E. coli*) gastroenteritis
- EATL (Enteropathy-associated
 T-cell lymphoma),
 223–5
- EBV (Epstein-Barr virus)
 gastric features, 197–8
 in inflammatory bowel disease
 (IBD), 392
 lymphoproliferative disorders,
 56, 398
 in smooth muscle tumours, 56
- EG. See Eosinophilic gastroen-
 teritis/gastroenterocoli-
 titis (EG/EGE)
- EGE. See Eosinophilic gastroen-
 teritis/gastroenterocoli-
 titis (EG/EGE)
- Ehlers-Danlos syndrome, 95–6
- Emphysematous gastritis, 197
- Endocrine cells
 duodenal mucosa and, 150
 gastric mucosa and, 143–5
- Endometriosis of GI tract, 428–9
 biopsies and, 429
 general features, 429
 immunochemistry and, 429
 intestinal mucosa
 distinguished, 429
 lower GI tract features, 379
 as mimic of inflammatory
 bowel disease (IBD), 379
 polypoid endometriosis, 429
- Enteric fever, 265–6
 differential diagnosis, 266
- Enterobius vermicularis
 (pinworm), 279–80
- Enterocolic (lymphocytic)
 phlebitis, 98
- Enteropathy-associated T-cell
 lymphoma (EATL),
 223–5
- EO. See Eosinophilic oesophagi-
 titis (EO)
- Eosinophilic (allergic) gastritis,
 188
- Eosinophilic colitis, drug-
 induced, 74
- Eosinophilic duodenitis, 209
- Eosinophilic gastroenteritis/
 gastroenterocolitis
 (EG/EGE)
 in children, 104–5
 diagnosis, 105
 pathogenesis, 105
 prevalence of, 104–5
 symptoms of, 105
 diagnosis, 298

- eosinophil numbers in, versus normal, 348–9
histology, 298
tissue sampling, 298
- Eosinophilic oesophagitis (EO), 172–5
basic features, 175
biopsies and, 3, 4, 173–4, 175
clinical features, 3, 4
diagnosis, 173–5
pathogenesis, 173
prevalence of, 173
symptoms of, 3, 173
- Eosinophils
causes of eosinophil-rich infiltrates, 21
causes of gastric eosinophil infiltrates, 188
in inflammatory bowel disease (IBD), 348–9
- Epithelium
duodenal mucosa, epithelial cells, 151, 287–9
epithelial neoplasms, 55
follicle-associated epithelium (FAE), 248, 249, 287–9
gastric mucosa
epithelial cells, 143, 144
surface and foveolar epithelium, 140–2
ileal mucosa, 245–6, 287–9
follicle-associated epithelium (FAE), 248, 249, 287–9
intraepithelial lymphocytes (IELs), 249
intraepithelial lymphocytes (IELs)
in coeliac disease (CD), 216
drug-induced increase, 69
in duodenal mucosa, 152, 208–9, 226–9
assessment, 223
causes of increase, 219
in ileal mucosa, 249, 287–9
in large intestinal mucosa, 254
in lymphocytic colitis, 312–13
in lymphocytic gastritis, 190
in lymphocytic oesophagitis, 175–6
in oesophageal mucosa, 134
large intestinal mucosa
epithelial cells, 250–3
intraepithelial lymphocytes (IELs), 254
oesophageal mucosa, 137
- Epstein-Barr virus (EBV)
gastric, 197–8
in inflammatory bowel disease (IBD), 392
lymphoproliferative disorders and, 56, 398
mesenchymal tumours and, 56
- Escherichia coli (E. coli)
gastroenteritis, 268–9
clinical features, 270
differential diagnosis, 268
general features, 268–9
macroscopic features, 270
microscopic features, 270
practical considerations, 270
symptoms of, 268–9
- Esophagitis. *See* Oesophagitis
- Esophagus. *See* Oesophagus
- FAE (Follicle-associated epithelium), 248, 249, 287–9
- FEG. *See* Focally enhanced gastritis (FEG)
- Fibroblasts
in duodenal mucosa, 150–1
in radiation damage, 34
- Fibroepithelial polyps, 435–6
causes, 436
granulomas and, 436
histological features, 436
types of, 436
- Fibrosing colonopathy (FC), 111–12
- Filamentous fungi
aspergillus, 275
oesophagitis, 172
basidiobolomycosis, 276–7
differential diagnosis, 276
mucormycosis, 275–6
practical considerations, 276
- Fistulas
anal/perianal fistulas
causes, 396, 437
histology, 396–7, 437
as complication of
inflammatory bowel disease (IBD), 396
diagnosis, 396–7
granulomas, 396–7
multinucleate giant cell reaction, 396
defined, 396–7
- Flagellates
Chagas disease, 278
Cryptosporidium parvum, 278–9
differential diagnosis, 279
- Focal active colitis
drug-induced, 73, 351–2, 374–6
- Focally enhanced gastritis (FEG), 107, 188, 241
inflammatory bowel disease (IBD) and, 240, 241
- Follicle-associated epithelium (FAE), 248, 249, 287–9
- Foveolae, 140–2
- Fungal infections. *See also specific infection*
aspergillus, 275
oesophagitis, 172
filamentous fungi
aspergillus, 275
basidiobolomycosis, 276–7
culture for diagnosis, 276
differential diagnosis, summary, 276
mucormycosis, 275–6
fungal gastritis, 198
fungal oesophagitis, 172
aspergillus oesophagitis, 172
candida oesophagitis, 172
other fungal infections, 172
histoplasmosis, 277
differential diagnosis, 277
immunosuppression and, 54–5
in lower GI tract, 275–8 (*See also specific infection*)
Penicillium marneffeii, 277–8
differential diagnosis, 278
yeast, 277–8
histoplasmosis, 277
Penicillium marneffeii, 277–8
- GALT (Gut-associated lymphoid tissue), 246–8, 249
- Gastric antral vascular ectasia (GAVE), 90–1
clinical features, 93
histology, 93
portal hypertensive gastroenteropathy distinguished, 93
- Gastric atrophy
biopsies and, 5–6, 7
clinical and endoscopic features, 5–6
- Gastric epithelial dysplasia (GED)
gastritis-associated dysplasia, 121–2
general features, 121
polypoid gastric dysplasia, 122
precursor lesions of invasive neoplasia, 121
pyloric gland adenoma, 122
rare types of, 122
- Gastric metaplasia of small intestinal mucosa, 208, 292
gastric heterotopia distinguished, 208
general features, 208
histology, 208, 291, 292
pseudopyloric metaplasia, 291, 292
pyloric gland metaplasia, 291, 292
ulcer-associated cell lineage, 291, 292
- Gastric mucosa
anatomical location and, 142–3
anatomy of stomach, 140
drug-induced disease of, 66
endocrine cells, 143–5
epithelial cells, 143, 144
foveolae, 140–2
gastro-oesophageal junction (GOJ), 137–8
general features, 140
glands, 141–2
heterotopia, 145–7
inflammatory cells, 145
lamina propria, 145, 147
normal epithelial cells, 144
normal mucosa, 140, 144, 147
oesophageal mucosa distinguished, 137
surface epithelium, 140–2
- Gastric polyps, biopsies and, 5, 7
- Gastric ulcer
biopsy and, 5, 7
clinical and endoscopic features, 5
- Gastritis
acute erosive gastritis, 187
acute gastritis, 187
acute haemorrhagic gastritis, 187
acute stress gastritis, 187
aetiology in relation to type of inflammation, 184
approach to diagnosis, 186
atrophic autoimmune pangastritis, 194
atrophic gastritis, 186–7
autoimmune gastritis, 192–4
Candida albicans, 198
causes of, 6, 184
collagenous gastritis, 187
emphysematous gastritis, 197
eosinophilic (allergic) gastritis, 188
causes of gastric eosinophilic infiltrates, 188
erosive gastritis, 187
focally enhanced gastritis (FEG), 188
inflammatory bowel disease (IBD) and, 241
fungal gastritis, 198
gastritis-associated dysplasia, 121–2
gastropathy versus, 181–2
granulomatous gastritis, 188–9, 241
causes, 189
haemorrhagic gastritis, 187
Helicobacter pylori gastritis
anatomical distribution, 195, 196
ancillary methods of detecting, 195
biopsies and, 5
complications, 195, 196
culture of biopsy specimens, 195
general features, 194–5, 196
histochemical stains, 195–6
histology, 196
identification of, 195–6
immunochemistry, 195
indications, 7
other Helicobacter species, 196
PCR, 195
practical considerations, 197
weight loss surgery and, 196–7

Index

- Gastritis (cont.)
 histological classification of generally, 180
 ICD-10, 180
 Kyoto global consensus, 180
 Sydney system, 180–1
 updated Sydney system, 181
 hypertrophic gastritis, 187
 infectious gastritis, 194
 ischaemic gastritis, 189–90
 lymphocytic gastritis, 190
 associations, 191
 endoscopy, 191
 general features, 191
 histology, 191
 medical therapy-related
 gastritis, 66, 184, 199
 chemotherapy and, 66, 68, 200–1
 colchicine, 67
 doxycycline and, 200
 immunomodulatory agents and, 200
 immunosuppressive agents and, 200
 infliximab, 200
 injury patterns, 66
 iron pill-associated gastritis, 66, 199
 mycophenolate mofetil (MMF) and, 56–7, 200
 non-steroid anti-inflammatory drugs (NSAIDs) and, 6, 66, 199–200
 olmesartan and, 200
 OsmoPrep, 67, 199
 radiation and, 40, 41, 200–1
 reactive/chemical
 gastropathy, 66–7, 190–1
 recreational drugs and, 201
 specific drugs, 67–8
 tablet or crystal deposition and, 66, 199
 ulceration, 67
 yttrium-90 microsphere selective internal radiation, 41, 67–8, 200–1
 Mott cell gastritis, 191–2
 overview, 186
 parasitic gastritis, 198–9
 pattern of inflammation as guide to aetiology, 184
 patterns of, 186–92
 phlegmonous gastritis, 197
 reactive gastritis, 190–1
 Russell body gastritis, 191–2
 stress gastritis, 187
 tuberculosis (TB), 199
 ulcerative colitis (UC) involving stomach, 241
 viral gastritis, 168
 cytomegalovirus (CMV), 197
 Epstein-Barr virus (EBV), 197–8
 Herpes simplex virus (*See* Herpes simplex virus (HSV))
 Herpes varicella zoster, 197
 xanthogranulomatous gastritis, 192
 Gastroenteritis, viral
 adenovirus
 clinical features, 260–2
 general features, 260–2
 histology, 53, 260–2, 294, 295
 immunosuppression and, 53
 in lower GI tract
 differential diagnosis, 261
 practical considerations, 261
 general features, 295
 norovirus, 294, 295
 other viruses, 295
 rotavirus, 293–4, 295
 Gastrointestinal biopsies. *See* Biopsies of GI tract
 Gastro-oesophageal junction (GOJ), 137–8
 intestinal metaplasia of, Barrett's oesophagus distinguished, 164
 Gastro-oesophageal reflux disease (GORD)
 clinical features, 3, 4, 157
 diagnosis, 157
 endoscopy, 157
 histological definitions, 157–9
 main histological features, summary, 159
 prevalence of, 157
 symptoms of, 157
 Gastropathy, 181–2. *See also* Gastritis
 GAVE. *See* Gastric antral vascular ectasia (GAVE)
 Giardiasis, 209–10
 common variable immune deficiency (CVID), association with, 210
 histology, 209–10
 as possible complication of inflammatory bowel disease (IBD), 393–4
 prevalence of, 209–10
 setting, 210
 Glycogenic acanthosis, 137
 Goblet cells in Barrett's oesophagus, 163
 GOJ. *See* Gastro-oesophageal junction (GOJ)
 Gonorrhoeal proctitis, 275
 microscopic pathology, 275
 GORD. *See* Gastro-oesophageal reflux disease (GORD)
 Graft-versus-host disease (GvHD)
 acute GvHD, 57–9
 histological features, summary, 60
 as mimic of inflammatory bowel disease (IBD), 369–70, 372
 chronic GvHD, 59–60
 as mimic of inflammatory bowel disease (IBD), 370, 372–3
 cryptolytic granulomas in, 59–60
 histological grading system, 59
 mycophenolate mofetil and, 56–7, 376
 Granulomas
 anal tags and, 436
 causes in intestine, 341
 cryptolytic granulomas, 340, 341
 in diversion proctocolitis, 361
 in diverticular colitis, 357–9
 in GvHD, 59–60
 in inflammatory bowel disease (IBD), 345–7
 fistulas and, 396–7
 granulomatous gastritis, 188–9, 241
 causes, 189
 inflammatory bowel disease (IBD) and, 345–7
 Crohn's disease versus UC, value, 341
 gastric granulomas in, 188–9, 240–1
 histological features, 331
 IBD versus other causes, value, 331–41
 oesophageal granulomas, 239
 in upper GI IBD, value for diagnosis, 236, 237
 oleogranulomas, 444
 sarcoidosis and, 14
 tuberculosis (TB) and, 362–6, 396
 Yersiniosis and, 364
 Gut-associated lymphoid tissue (GALT), 246–8, 249
 GvHD. *See* Graft-versus-host disease (GvHD)
 Haemophilus ducreyi, 439
 Haemorrhoids, 434–5
 contents of pathology report, 435
 possible incidental changes, 435
 types of specimen, 435
 Helicobacter pylori gastritis
 anatomical distribution, 195, 196
 ancillary methods of detecting, 195
 biopsies and, 5
 indications, 7
 complications, 195, 196
 culture of biopsy specimens, 195
 general features, 194–6
 histochemical stains, 195–6
 histology, 196
 identification of, 195–6
 immunohistochemistry, 195
 other Helicobacter species, 196
 PCR, 195
 practical considerations, 197
 weight loss surgery and, 196–7
 Helminths
 Ancylostoma duodenale (hookworm), 280–1
 Ascaris lumbricoides (roundworm), 280
 clinical features, 280
 differential diagnosis, 280
 Enterobius vermicularis (pinworm), 279–80
 macroscopic pathology, 280
 microscopic pathology, 280
 Necator americanus (hookworm), 280–1
 strongyloidiasis, 281
 clinical features, 281
 duodenitis and, 210
 macroscopic pathology, 281
 microscopic pathology, 281
 trichuris trichiura (whipworm), 280
 Hepatitis C, drug-induced disease of large intestine and, 77
 Hereditary haemorrhagic telangiectasia, 94–5
 Herpes simplex virus (HSV)
 anogenital, 439
 gastritis, 197
 human immunodeficiency virus (HIV) and, 439
 mimicking radiation change, 33–4
 proctitis
 clinical features, 263
 differential diagnosis, 263
 histological features, 261–2, 263
 macroscopic pathology, 263
 Herpes varicella zoster, 197
 Heterotopia
 in duodenum, 153–4
 heterotopic gastric mucosa, 212
 heterotopic pancreas, 145–7, 212–13
 gastric metaplasia, gastric heterotopia distinguished, 208
 in large intestine, heterotopic gastric mucosa, 256
 in oesophagus, 138–40
 in stomach, pancreatic heterotopia, 145–7
 Hidradenitis suppurativa, 438
 anal Crohn's disease compared, 438

- Histiocytes in large intestinal mucosa, 254–5
- Histoplasmosis, 277
differential diagnosis, 277
gastric, 188–9, 198
oesophageal, 172
- HIV. *See* Human immunodeficiency virus (HIV)
- Hookworm
clinical features, 280
differential diagnosis, 280
macroscopic features, 280
microscopic features, 280
- HSV. *See* Herpes simplex virus (HSV)
- Human immunodeficiency virus (HIV)
anal diseases in HIV-positive patients, 438–9
aetiologies, 438
clinical features, 438
HIV-associated lesions, summary, 439
incidental lesions, summary, 439
anal fissures and, 435
Chlamydia trachomatis (lymphogranuloma venereum) and, 52, 362–4, 439
enterocolopathy
histology, 262
as mimic of inflammatory bowel disease (IBD), 362–4
possible aetiologies, 262
Haemophilus ducreyi and, 439
Herpes simplex virus (HSV) and, 439
lymphogranuloma venereum (LGV) (Chlamydia trachomatis) and, 52, 362–4, 439
Molluscum contagiosum and, 439–40
syphilis and, 440
- Human papilloma virus (HPV), anal diseases and, 442
- Hyperplasia
hyperplastic polyps versus sessile serrated polyps, 123
idiopathic myointimal hyperplasia of mesenteric veins (IMHMV), 94, 95
lymphoid hyperplasia of small intestine
differential diagnosis, 305
immunohistochemistry and, 305
neoplasia distinguished, 304–6
(nodular) lymphoid hyperplasia of GI tract (NLH), 55
Hypertrophic gastritis, 187
- Iatrogenic diseases
anal oleogranuloma, 444
drug-induced disease (*See* Drug-induced disease)
pouch surgery, 444
radiation damage (*See* Radiation damage)
- IBD. *See* Inflammatory bowel disease (IBD)
- Idelalisib, drug-induced disease of large intestine and, 76
- Idiopathic myointimal hyperplasia of mesenteric veins (IMHMV), 94, 95
- IELs. *See* Intraepithelial lymphocytes (IELs)
- IgA vasculitis, 97–8
as mimic of inflammatory bowel disease (IBD), 381
- IgG4 in inflammatory bowel disease (IBD), 381
- IgG4-related disease (IgG4-RD), 24
clinical features, 21
course and treatment, 24
diagnosis, 22–4
HISORT criteria, 22
Japanese Comprehensive Diagnostic Criteria, 22
differential diagnosis, 24
epidemiology, 21
GI tract involvement, 21–2, 24
histology, 22–4
liver involvement, 21–2
as mimic of inflammatory bowel disease (IBD), 381
mimics, 24
overview, 21
pancreas involvement, 21–2
sites of involvement, 21
- Ileal mucosa
anatomy of ileum and, 245
duodenum compared, 249, 287–9
epithelium, 245–6, 287–9
follicle-associated epithelium (FAE), 248, 249, 287–9
gut-associated lymphoid tissue (GALT), 246–8, 249
inflammatory cells, 246–9
intraepithelial lymphocytes (IELs), 249, 287–9
jejunum compared, 287–9
lamina propria, 246–9
lymphocytes, 249
lymphoid follicles, 246–8, 249, 287–8
mast cells, 249
neutrophils, 249
Peyer's patch, 246–8, 287–8
plasma cells, 249
submucosa, 250
- Ileal pouch anal anastomosis (IPAA)
generally, 416
in Crohn's disease, 412–15
diagnosis, 415
reasons for, 415
cuffitis, 412–13
development of, 410
dysplasia and, 414
indications for IPAA, 410, 411
malignancy and, 414
pathology, overview, 410
pouchitis, 410–15
pre-pouch ileitis, 414–15
types of biopsies, 411
in ulcerative colitis (UC), 413–14
- Ileal pouch disorders
classification, 410–11
rectal cuff, 412–13
functional, 411
inflammatory and infectious, 411
neoplastic, 411
pouchitis (*See* Pouchitis)
surgical and mechanical, 411
- Ileitis
acute enteritis
infectious causes, 293–6
non-infectious causes, 295–8
“backwash” ileitis, 341–3
bacterial enteritis, 294–6
biopsies, value of, 289–90
causes, 292–3
infectious causes, 293–6
non-infectious causes, 295–8
summary, 293
chronic ileitis
causes, 297–302
clues to cause, 298
chronicity, histological features suggesting, 250, 293
in Crohn's disease, 341–3
characteristic features, 300
differential diagnosis, 9
early microscopic features, 300
general features, 300
villous abnormalities, 300
differential diagnosis, 9
drug-induced, 300
ipilimumab and, 68, 71–2, 300
mycophenolate mofetil (MMF) and, 56–7, 300, 376
non-steroidal anti-inflammatory drugs (NSAIDs) and, 300
olmesartan and, 68, 70–1, 300
eosinophilic enteritis/jejunitis/ileitis, 297, 298
histological features, 290–1, 292
inflammatory bowel disease (IBD) and, 341–3
“backwash” ileitis, 341–3
ipilimumab and, 68, 71–2, 300
isolated ileitis, 302–3
microscopic colitis and, 297
“microscopic enteritis,” 292
causes, 292
general features, 292
range of microscopic changes, 292
mycophenolate mofetil (MMF) and, 300
non-steroidal anti-inflammatory drugs (NSAIDs) and, 300
olmesartan and, 68, 70–1, 300
pre-pouch ileitis, 414–15
in ulcerative colitis (UC), 301, 341–3
“backwash” ileitis, 341–3
general features, 301
histology, 301
value of upper GI biopsy in determining cause, 237
viral gastroenteritis and adenovirus, 295
general features, 260–2
histology, 53, 260–2, 294, 295
immunosuppression and, 53
practical considerations, 261
clinical features, 260–2
general features, 295
norovirus, 294, 295
other viruses, 295
rotavirus, 294, 295
- Ileum
anatomy of, 245, 287
biopsies of
generally, 306
focal and stenosing lesions, 303
value of, 289–90
gastric metaplasia, 208, 291, 292
gastric heterotopia distinguished, 208
general features, 208
histology, 208, 291, 292
pseudopyloric metaplasia, 291, 292
pyloric gland metaplasia, 291, 292
ulcer-associated cell lineage, 291, 292
mucosa (*See* Ileal mucosa)
- IMHMV (Idiopathic myointimal hyperplasia of mesenteric veins), 94
- Immune dysfunction, polyendocrinopathy, enteropathy, X-linked (IPEX)
immunosuppression and, 62
as mimic of inflammatory bowel disease (IBD), 378

Index

- Immunomodulatory agents, 77–8
- colitis as mimic of
- inflammatory bowel disease (IBD), 376
 - gastritis and, 200
 - PD-1/PD-L1 inhibitor gastroenterocolitis, 77–8
- Immunosuppression
- bacterial infections and, 52
 - categories, 52
 - chronic granulomatous disease, 61
 - common variable immunodeficiency (CVID), 61
 - drugs and
 - mycophenolate mofetil (MMF), 56–7
 - other drugs, 57
 - epithelial neoplasms, 55
 - fungal infections and, 54–5
 - gastritis and, 200
 - human immunodeficiency virus (HIV) and, 61
 - immune dysfunction,
 - polyendocrinopathy, enteropathy, X-linked (IPEX), 62
 - infective oesophagitis and, 169
 - leukaemia, neutropaenic enterocolitis/typhlitis in, 61, 270
 - lymphoreticular proliferations and
 - lymphomas, 55
 - nodular lymphoid hyperplasia (NLH), 55
 - post-transplant lymphoproliferative disorder (PTLD), 55–6
 - mesenchymal neoplasms, 56
 - neutropaenic enterocolitis in, 61, 270
 - overview of GI impact, 52
 - parasitic infections and, 54–5
 - proliferative lesions, summary, 56
 - summary of GI impact, 62
 - transplantation and
 - acute graft-versus-host disease (GvHD), 57–9, 60
 - biopsies, clinical data needed for optimal assessment, 62
 - bone marrow transplants, 60
 - chronic graft-versus-host disease (GvHD), 59–60
 - cord colitis syndrome, 60
 - liver transplants, 60
 - miscellaneous transplant-related gastrointestinal diseases, 60–1
 - renal transplantation, relationship with
 - inflammatory bowel disease (IBD), 353
 - typhlitis in, 61, 270
 - viral infections and
 - adenovirus, 53
 - cytomegalovirus (CMV), 53
 - other viruses, 53–4
 - Wiskott-Aldrich syndrome, 61
- Infections. *See also specific infection*
- bacterial infections (*See* Bacterial infections)
 - chronic infective diarrhoea
 - bacterial causes, 294
 - definition of, 294
 - viral causes, 294
 - fungal infections (*See* Fungal infections)
 - ileal pouch infection, 411
 - infectious gastritis, overview, 194
 - infective colitis, inflammatory bowel disease (IBD) distinguished, 335–7
 - oesophagitis (*See* Oesophagitis)
 - parasitic infections (*See* Parasitic infections)
 - in relation to inflammatory bowel disease (IBD)
 - clinical relevance, 388
 - diagnosis, 388–9
 - as differential diagnosis, 388
 - histological detection, 389
 - importance for pathogenesis, 388
 - relationship between IBD and infection, 388
 - summary, 394–5
 - superinfection of doubtful significance, 388
 - viral infections (*See* Viral infections)
- Inflammatory bowel disease (IBD)
- apoptosis in, 347–8
 - biopsies and
 - appearances in children, 106–7
 - new diagnosis, 9, 10
 - surveillance for colorectal carcinoma (CRC), 9, 10
 - upper GI tract involvement, 243
 - in children
 - adults compared, 106, 107, 108
 - biopsy appearances, 106–7
 - Crohn's disease, 108–10
 - diagnosis, 106
 - IBD unclassified (IBDU), 108–9
 - monogenic IBD-like colitides, 109–10
 - monogenic/very early onset IBD, 109–10
 - pathogenesis, 106
 - prevalence of, 105–6
 - stomach, 237, 240
 - subgroups, 110
 - ulcerative colitis (UC), 107–8
 - upper GI tract involvement, 237
 - colorectal dysplasia in, 125
 - complications (*See* Inflammatory bowel disease (IBD)—complications)
 - Crohn's disease (*See* Crohn's disease)
 - cutaneous manifestations of, 25
 - diagnosis (*See* Inflammatory bowel disease (IBD)—diagnosis)
 - diverticular colitis and, 357–9, 421, 424, 425
 - diverticulosis and, 418
 - dysplasia in, 125
 - eosinophils in, 348–9
 - granulomas in, 345–7
 - microscopic colitis and, 320–1
 - distinguished, 322, 374
 - mimics (*See* Inflammatory bowel disease (IBD)—mimics)
 - reporting of biopsies (*See* Reporting inflammatory bowel disease (IBD))
 - subclassification as ulcerative colitis (UC) of Crohn's disease, 337, 343, 346
 - ulcerative colitis (*See* Ulcerative colitis (UC))
 - upper GI tract involvement (*See* Inflammatory bowel disease (IBD)—upper GI tract involvement)
- Inflammatory bowel disease (IBD)—complications
- amoebiasis, 392–4
 - bacterial infections
 - Campylobacter jejuni, 394
 - Clostridioides difficile, 394
 - tuberculosis (TB), 394
 - bacterial superinfection, 394
 - Blastocystis hominis, 394
 - Campylobacter jejuni, 394
 - Clostridioides difficile, 394
 - colorectal carcinoma (CRC) non-IBD CRC compared, 397
 - pathology, 397
 - risk factors, 397
 - colorectal dysplasia, 397–8
 - cytomegalovirus (CMV), 391
 - biopsy reports and, 406
 - clinical features, 261
 - diagnosis, 389–91
 - DNA real-time polymerase chain reaction, 392
 - H&E inclusions, 392
 - histological factors, 261, 391
 - inclusions, 391, 392
 - immunochemistry and, 392, 393
 - interpretation of, 261, 393
 - macroscopic pathology, 261
 - mimics of inclusions, 391
 - prevalence in IBD of, 389
 - tests for, 391–2
 - DNA real-time polymerase chain reaction, 392
 - underlying IBD in new patient with CMV, 391
- Epstein-Barr virus (EBV), 392
- fistula, 396
 - causes, 396, 437
 - in Crohn's disease, 396
 - definition, 396–7
 - diagnosis, 396–7
 - granulomas, 396–7
 - histology, 396–7, 437
 - giardiasis, 393–4
 - ileal pouch anal anastomosis cancer, 398
 - infections
 - relationship between IBD and infection, 388
 - summary, 394–5
 - superinfection of doubtful significance, 388
 - lymphoma, 398
 - lymphoproliferative disorders, 398
 - multinucleate giant cell reaction, 396
 - neoplasia
 - colorectal carcinoma (CRC) (*See* Colorectal carcinoma (CRC))
 - colorectal dysplasia, 397–8
 - ileal pouch anal anastomosis cancer, 398
 - lymphoma, 398
 - lymphoproliferative disorders, 398
 - parasitic infections
 - amoebiasis, 392–4
 - blastocystis hominis, 394
 - giardiasis, 393–4
 - pouch cancer, 398
 - tuberculosis (TB), 394
 - Inflammatory bowel disease (IBD)—diagnosis
 - activity, clinical significance, 351
 - Nancy and Robarts histological indices, 351
 - suggested grading scheme, 351
 - combinations of features, 351
 - Crohn's disease versus ulcerative colitis (UC), 346
 - contour of mucosal surface, 344

- disproportionate submucosal inflammation, 344–5
- focality of acute inflammation, 344–6
- focal or segmental changes, 341, 345
- focal or segmental crypt distortion, 341, 345
- gradient between sites, 344
- granulomas, 341
- ileal involvement, 341–3
- non-diffuse (focal or patchy) chronic inflammation, 341
- reliable distinguishing features, 341–3, 344
- summary, 346
- definitions of histological features, 338
- distribution of disease and assessment of, 327
- discontinuity in ulcerative colitis (UC), 329–30
- distribution between sites, 328
- distribution of architectural changes within single site, 328
- distribution of chronic inflammation within single site, 328
- new IBD, diagnostic value, 327–8
- significance for classification as ulcerative colitis (UC) or Crohn's disease, 327–8
- terminology for distribution, 328
- drug efficacy, value of, 350–1
- focal active colitis, 351–2
- general considerations for diagnosis, 327
- granulomas and
- favouring Crohn's disease over UC, 341
 - favouring IBD over other causes, 331–41
 - histological features, 331
- histological features that may occur in IBD, 329–38
- acute inflammation, 331
 - architectural changes, 331
 - chronic inflammation, 331
 - definitions of features, 338
 - epithelial changes, 331
 - giant cells, 331
 - granulomas, 331
- IBD versus other causes of colorectal inflammation, 340, 342
- activity, 335
 - architecture, 331
 - basal giant cells, 332
 - basal lymphoid aggregates, 332
 - basal plasmacytosis, 329–39
 - crypt atrophy, 331
 - crypt branching, 331
 - crypt distortion, 331
 - granulomas, 331–41
 - irregular mucosal surface, 331
 - lamina propria chronic inflammation, 332–3
 - lamina propria hypercellularity, 332–3
 - Paneth cell metaplasia, 334–5
 - plasma cell gradient, 329–31
 - reliable distinguishing features, 329–31
 - summary, 340, 342
 - villous mucosal surface, 331
- infective colitis distinguished, 335–7
- longstanding/treated IBD, 349–50
- new endoscopic techniques, 353
- primary sclerosing cholangitis, effect on pathology, 352
- questions pathologist should ask clinician, 327
- renal transplantation, relationship with IBD, 353
- role of histology in, 325, 353
- time and treatment, effect on pathology, 349
- early IBD, 349, 350
 - importance of distinction, 349
 - longstanding IBD, 349–50
 - relationship between duration of symptoms and frequency of histological features, 349
 - treated IBD, 349–50
- ulcerative colitis (UC) versus Crohn's disease, 343
- activity, 339
 - crypt architectural changes, 337–43
 - crypt atrophy, 337–43
 - gradient of changes between sites, 339–40
 - ileal inflammation, absence of, 339
 - mucin depletion, 337
 - reliable distinguishing features, 337–9
 - summary, 343
 - villiform mucosal surface, 337–43
- Inflammatory bowel disease (IBD)—mimics
- acute graft-versus-host disease (GvHD), 369–70, 372
 - amoebiasis, 364–8
 - autoimmune enteropathy (AIE), 373
 - Behçet's disease, 366–9
 - checkpoint inhibitors, 376
 - chemotherapy, 376
 - Chlamydia trachomatis (lymphogranuloma venereum), 362–4
 - summary, 362–4, 364 - chronic graft-versus-host disease (GvHD), 370, 372–3
 - chronic granulomatous disease, 377–8
 - common variable immunodeficiency (CVID), 376–7
 - diagnosis and clinical management, effect on, 357, 384
 - diversion proctocolitis (DPC), 358–62
 - diverticular colitis, 357–9
 - endometriosis, 379
 - human immunodeficiency virus (HIV) enterocolopathy, 362–4
 - IgA vasculitis, 97–8, 381
 - IgG4-related disease (IgG4-RD), 381
 - immune dysfunction, polyendocrinopathy, enteropathy, X-linked (IPEX), 378
 - ipilimumab colitis, 376
 - ischaemia, 368–70
 - lymphogranuloma venereum (LGV) (Chlamydia trachomatis), 362–4
 - summary, 362–4, 364 - mass lesions, 366
 - mastocytosis, 384
 - microscopic colitis, 320–1, 370–4
 - mucosal prolapse, 368–71
 - mycophenolate mofetil (MMF) colitis, 376
 - non-steroidal anti-inflammatory drugs (NSAIDs) colitis, 374–5
 - pneumatosis intestinalis/pneumatosis coli, 380–1
 - radiation damage, 45, 367
 - sarcoidosis, 364–6
 - summary of mimics, 384
 - syphilis, 362–4
 - summary, 362–4, 364 - tuberculosis (TB), 362–6
 - Crohn's disease, features resembling, 366 - Wiskott-Aldrich syndrome, 379
 - X-linked agammaglobulinaemia, 377
 - yersiniosis, 364
- Inflammatory bowel disease (IBD)—upper GI tract involvement, 236, 243
- in children, 107–8, 237
 - considerations before diagnosis, 236–8
- Crohn's disease and
- distinction from other causes of inflammation, 236, 237
 - distinguishing from ulcerative colitis (UC), 237
- duodenum, 242–3
- endoscopy, 236
- frequency of selected histological features, 242
- granulomas and
- diagnostic value of, 236, 237
 - gastric granulomas, 240–1
 - oesophageal granulomas, 239
- new diagnosis of IBD, 237
- oesophagus
- distinction from other causes of inflammation, 238, 239
 - lymphocytic oesophagitis (LO), 239
 - oesophageal granulomas, 239
 - oesophageal ulcerative colitis (UC), 239
- paediatric, 237
- severity of inflammation, value for classification, 243
- stomach
- in children, 240
 - distinction from other causes of inflammation, 239–40
 - focally enhanced gastritis (FEG), 240, 241
 - gastric granulomas, 240–1
 - gastric ulcerative colitis (UC), 241
 - prevalence of, 239–40
 - summary, 243
- ulcerative colitis (UC) and
- distinguishing from Crohn's disease, value for, 237
 - implications of new upper GI disease for existing diagnosis of UC, 243
 - oesophagus, 239
 - stomach, 241
- Inflammatory cloacogenic polyps, 441–2
- Inflammatory vasculitides, 96–8
- clinical features, 97–8
 - pathological features, 97–8
- Infliximab, gastritis and, 200
- Intestinal metaplasia, Barrett's oesophagus (BE) distinguished, 164
- Intraepithelial lymphocytes (IELs)
- coeliac disease (CD), causes of increase in intraepithelial lymphocyte numbers, 249
 - in ileal mucosa, 249
 - intraepithelial lymphocytosis duodenitis and, 208–9

Index

- IELs (cont.)
risk of overcalling, 316
in large intestinal mucosa, 254
- IPAA. *See* Ileal pouch anal anastomosis (IPAA)
- IPEX (Immune dysfunction, polyendocrinopathy, enteropathy, X-linked)
immunosuppression and, 62
as mimic of inflammatory bowel disease (IBD), 378
- Ipilimumab
colitis, 71–2, 376
as mimic of inflammatory bowel disease (IBD), 376
ileitis and, 68, 300
small intestine, drug-induced disease of, 71–2
- Iron
iron deficiency anemia (IDA)
as indication for biopsy, 6, 7
iron pill-associated gastritis, 66, 179, 199
iron pill-associated oesophageal disease, 65, 66
- Ischaemia
acute intestinal ischaemia, 85–6, 89
acute oesophageal necrosis (AEN), 84–5
endoscopic features, 84
general features, 84
histological features, 84
macroscopic features, 84
risk factors, 84
chronic mesenteric ischaemia, 85–6, 89
diagnosis, general considerations, 84
drug-induced ischaemic colitis, 73–4
ischaemic gastritis, 189–90
of large intestine, 85
acute mesenteric ischaemia, 85–6, 89
aetiologies, 85–6
chronic mesenteric ischaemia, 85–6, 89
differential diagnosis, 89–90
histology, 89
macroscopic features, 86–8
mesenteric venous thrombosis, 89
microscopic features, 86–8
as mimic of inflammatory bowel disease (IBD), 368–70
unusual patterns of colonic ischaemia, 88–9
“watershed” areas, 86
of oesophagus, 85
of small intestine, 85
acute mesenteric ischaemia, 85–6, 89
aetiologies, 85–6
chronic mesenteric ischaemia, 85–6, 89
differential diagnosis, 89–90
macroscopic features, 86–8
mesenteric venous thrombosis, 89
microscopic features, 86–8
of stomach, 85
- Ischaemic gastritis, 189–90
- Jejunitis, 295–8
primary eosinophilic jejunitis/ileitis, 297, 298
ulcerative jejunitis (UJ), 223
- Jejunum, anatomy of, 287
- Kawasaki disease, 97–8
- Kayexalate, drug-induced disease of small intestine and, 72
- Klebsiella oxytoca, 268–70
differential diagnosis, 270
- Kyoto global consensus, 180
- Lamina propria
inflammatory bowel disease (IBD), diagnosis and, 332–3
in normal duodenal mucosa, 151, 153
in normal gastric mucosa, 145, 147
in normal ileal mucosa, 246–9
lymphocytes, 249
in normal large intestinal mucosa, 252–3
in normal oesophageal mucosa, 134–6, 137
radiation damage to large bowel, diagnosis and, 45–6, 47
- Large intestinal mucosa
acute inflammatory cells, 254
anatomy of large intestine and, 245
apoptosis, 256
architectural abnormality, risk of overcalling, 254, 317, 331, 338
chronic inflammatory cells, 252–3, 254
collagen band, 254
distorted crypts, 254
epithelium, 250–3
heterotopic gastric mucosa, 256
histiocytes, 254–5
intraepithelial lymphocytes (IELs), 252–3, 254
lamina propria, 252–3
macrophages, 254–5
muscularis mucosae, 256–7
normality, summary, 316
procedure-related changes, 256–7
submucosa, 256–7
- Large intestine
acute radiation damage, 44–5
atypia, 45
differential diagnosis, 45
epithelium, 45
histology, 45
inflammation, 45
miscellaneous changes, 45
anatomy of, 245
biopsy protocol
acute severe colitis, 10
colorectal carcinoma (CRC), 9–10
colorectal neoplasia, 10
colorectal polyps, 9–10
graft-versus-host disease, 10
inflammatory bowel disease (IBD), 9, 10
microscopic colitis, 8–9, 10
pouchitis, 9, 10
chronic radiation damage, 45–9
atypia, 45–7
crypts, 47
deeper layers, changes in, 47
differential diagnosis, 46–9
epithelium, 47
lamina propria, 45–6, 47
mechanisms, 48–9
mucosal vasculature, 47
submucosa, 47
drug-induced disease
biologic agents and, 77
cholestyramine, 74–5
crystal deposition and, 74–5
dasatinib, 76–7
dysplasia, cyclosporin as mimic of, 74
eosinophilic colitis, 74
focal active colitis, 73
hepatitis C treatment and, 77
idelalisib, 76
injury patterns, 73
ipilimumab, 71–2, 376
ischaemic colitis, 73–4
microscopic-type colitis, 74
non-steroidal anti-inflammatory drugs (NSAIDs), 75–6
PD-1 inhibitor gastroenterocolitis, 77–8
pneumatosis coli, 75
pseudomembranous colitis, 74
rituximab, 77
sevelamer, 74–5
specific drugs, 75–7
heterotopic gastric mucosa, 256
ischaemia of
generally, 85
acute mesenteric ischaemia, 85–6, 89
aetiologies, 85–6
chronic mesenteric ischaemia, 85–6, 89
differential diagnosis, 89–90
histology, summary, 89
macroscopic features, 86–8
mesenteric venous thrombosis, 89
microscopic features, 86–8
as mimic of inflammatory bowel disease (IBD), 368–70
unusual patterns of colonic ischaemia, 88–9
“watershed” areas, 86
mucosa (*See* Large intestinal mucosa)
radiation damage, 41–2
acute radiation damage, 44–5
chronic radiation damage, 45–9
risk factors for damage, 44
- Leukaemia, neutropaenic enterocolitis/typhlitis, 61, 270
- LGV. *See* Lymphogranuloma venereum (LGV) (Chlamydia trachomatis)
- Lichen planus, anal, 441
- Lichen sclerosus, anal, 441
- Liver
amyloidosis, liver involvement, 16
dermatological conditions and, 25
IgG4-related disease (IgG4-RD), liver involvement, 21–2
mastocytosis, liver involvement, 19
sarcoidosis, liver involvement, 13–14
transplantations, 60
- LO. *See* Lymphocytic oesophagitis (LO)
- Lymphocytic colitis
collagenous colitis distinguished, 320
differential diagnosis, 320
pathological features, 312
“Lymphocytic duodenitis,” 208–9
- Lymphocytic gastritis, 190
associations, 191
endoscopy, 191
histology, 191
- Lymphocytic oesophagitis (LO), 175, 176
associations, 176
diagnosis, 176
general features, 176
inflammatory bowel disease (IBD) and, 239
- Lymphogranuloma venereum (LGV) (Chlamydia trachomatis), 273–5, 362–4
clinical features, summary, 275

- human immunodeficiency virus (HIV) and, 52, 362–4, 439
- microscopic pathology, 275
- as mimic of inflammatory bowel disease (IBD), 362–4
- Lymphoid follicles in ileal mucosa, 246–8, 249, 287–8
- Lymphoid hyperplasia (nodular lymphoid hyperplasia) of small intestine, 55
- differential diagnosis, 305
- immunochemistry and, 305
- neoplasia distinguished, 304–6
- Lymphoid hyperplasia of GI tract, 55
- Lymphoma
- as complication of inflammatory bowel disease (IBD), 398
- enteropathy-associated T-cell lymphoma (EATL), 223–5
- immunosuppression and, 55
- Lymphoproliferative disorder as complication of inflammatory bowel disease (IBD), 398
- post-transplant lymphoproliferative disorder (PTLD), 55–6
- Macrophages in large intestinal mucosa, 254–5
- Mass lesions as mimic of inflammatory bowel disease (IBD), 366
- Mast cell disorders, 18
- Mastocytosis, 20
- classification of mast cell disorders, 18
- clinical features, 18–19
- course and treatment, 20
- diagnosis, 19–20
- eosinophil-rich inflammatory cell infiltrates, conditions characterised by, 21
- epidemiology, 18
- GI tract involvement, 19, 20
- histology, 19–20
- liver involvement, 19
- as mimic of inflammatory bowel disease (IBD), 384
- Mesenchymal neoplasms in setting of immunosuppression, 56
- Mesenteric venous thrombosis, 89
- Metaplasia
- gastric metaplasia of small intestinal mucosa, 208, 291, 292
- gastric heterotopia distinguished, 208
- general features, 208
- histology, 208, 291, 292
- intestinal metaplasia of stomach, Barrett's oesophagus distinguished, 164
- oesophageal mucosa, 138–40
- Paneth cell metaplasia, 334–5
- pseudopyloric metaplasia, 291, 292
- pyloric gland metaplasia, 291, 292
- ulcer-associated cell lineage, 291, 292
- Microscopic colitis
- anatomical distribution, 314–15
- ancillary staining, 313
- biopsies and, 8–9, 10
- clinical features, 311
- collagenous colitis
- differential diagnosis, 318–19
- lymphocytic colitis distinguished, 320
- pathological features, 311–12
- demographic features, 310
- diagnostic triad, 310
- differential diagnosis, 316–17
- collagenous colitis, 318–19
- lymphocytic colitis, 320
- drug-induced microscopic colitis, 74, 311
- endoscopic features, 311
- epidemiology, 310–11
- general features, 310
- historical background, 310
- ileum and, 297, 321
- incomplete microscopic colitis, 315–16
- inflammatory bowel disease (IBD) and, 320–1
- distinguished, 322, 374
- lymphocytic colitis
- collagenous colitis distinguished, 320
- differential diagnosis, 320
- pathological features, 311–12
- microscopic features, 311–14
- as mimic of inflammatory bowel disease (IBD), 320–1, 370–4
- pathogenesis, 311
- practical considerations, 315
- prevalence of, 310
- prognosis, 321–2
- small intestine and, 297, 321
- treatment, 321–2
- variants, 315
- “Microscopic enteritis,” 292
- causes, 292
- general features, 292
- range of microscopic changes, 292
- Microscopic-type colitis, drug-induced, 74
- Microsporidiosis, duodenitis and, 210
- Mimics
- of adenocarcinoma
- inflammatory cloacogenic polyps, 428
- prolapse at stomas, 428
- related to prolapse, 428
- of coeliac disease (CD), 8
- of IgG4-related disease (IgG4-RD), 24
- MMF. *See* Mycophenolate mofetil (MMF)
- Molluscum contagiosum, anal, 439–40
- Monogenic IBD-like colitides, 109–10
- Monogenic/very early onset IBD, 109–10
- Mott cell gastritis, 191–2
- MPA (Mycophenolate). *See* Mycophenolate mofetil (MMF)
- Mucin depletion, diagnosis of inflammatory bowel disease (IBD) and, 337
- Mucormycosis, 275–6
- differential diagnosis, 276
- Mucosa
- in children
- adult mucosa compared, 102–3
- morphology, 103
- duodenal mucosa, 147–50
- anatomy of duodenum, 147
- Brunner's glands, 153–4
- endocrine cells, 150
- epithelial cells, 147–50, 151
- summary, 152
- fibroblasts, 150–1
- general features, 147–50
- heterotopia, 153–4
- ileum compared, 249, 287–9
- inflammatory cells, 151–3
- intraepithelial lymphocytosis, 69, 208–9, 219, 226–9
- causes of, summary, 219
- lamina propria, 151, 153
- normal mucosa, 147–50, 152, 153, 206
- submucosa, 153–4
- gastric mucosa, 140
- anatomical location and, 142–3
- anatomy of stomach, 140
- drug-induced disease of, 67
- endocrine cells, 143–5
- epithelial cells, 143, 144
- foveolae, 140–2
- gastro-oesophageal junction (GOJ), 137–8
- glands, 141–2
- heterotopia, 145–7
- inflammatory cells, 145
- lamina propria, 145, 147
- normal epithelial cells, 144, 147
- normal mucosa, 140, 144, 147
- oesophageal mucosa distinguished, 137
- surface epithelium, 140–2
- ileal mucosa
- anatomy of ileum and, 245
- duodenum compared, 249
- epithelium, 245–6, 287–9
- follicle-associated epithelium (FAE), 248, 249, 287–9
- gut-associated lymphoid tissue (GALT), 246–8, 249
- inflammatory cells, 246–9
- intraepithelial lymphocytes (IELs), 247–8, 249
- lamina propria, 246–9
- lymphocytes, 249
- lymphoid follicles, 246–8, 249, 287–8
- mast cells, 249
- neutrophils, 249
- plasma cells, 249
- submucosa, 250
- ileal pouch anal anastomosis (IPAA) mucosa
- histology, 410–15
- scoring system for histological changes, 412–13
- large intestinal mucosa
- acute inflammatory cells, 254
- anatomy of large intestine and, 245
- apoptosis, 256
- architectural abnormality, risk of overcalling, 254, 317, 331, 338
- chronic inflammatory cells, 252–3, 254
- collagen band, 254
- epithelium, 250–3
- heterotopic gastric mucosa, 256
- histiocytes, 254–5
- intraepithelial lymphocytes (IELs), 252–3, 254
- lamina propria, 252–3
- macrophages, 254–5
- muscularis mucosae, 256–7
- normality, summary, 316, 338
- procedure-related changes, 256–7
- submucosa, 256–7
- oesophageal mucosa, 131–4, 137
- anatomy of oesophagus and, 131
- epithelium, 137
- gastric mucosa distinguished, 137

Index

- Mucosa (cont.)
gastro-oesophageal junction (GOJ), 137–8
general features, 131–4
glycogenic acanthosis, 137
heterotopia in, 138–40
inflammatory cells, 134
lamina propria, 134–6, 137
metaplasia, 138–40
muscularis mucosae, 134–6
normal mucosa, summary, 137
papillae, 134–5, 137
submucosa, 136, 137
pouch mucosa
histology, 410–15
scoring system for histological changes, 412–13
prolapse (*See* Mucosal prolapse)
- Mucosal prolapse, 425–6
adenocarcinoma, as mimic of, 428
prolapse at stomas, 428
related to prolapse, 428
diverticulosis and, 418
general features, 426
histology, summary, 426
as mimic of adenocarcinoma inflammatory cloacogenic polyps, 428
as mimic of inflammatory bowel disease (IBD), 368–71
- Muscularis mucosae
ileal, 250
large intestinal, 256–7
oesophageal, 134–6
- Mycobacterial diseases
intestinal
clinical features, 273
macroscopic pathology, 273
microscopic pathology, 273
tuberculosis (TB), 298
Mycobacterial avium
intracellulare, 272
differential diagnosis, 272
mycobacterium tuberculosis (TB), 271–2, 298
differential diagnosis, 272
granulomas, Crohn's disease compared, 366
- Mycophenolate mofetil (MMF), 56–7
colitis as mimic of inflammatory bowel disease (IBD), 376
gastritis and, 200
graft-versus-host disease (GvHD) and, 56–7, 376
ileitis and, 69–70, 300
- Mycophenolate (MPA). *See* Mycophenolate mofetil (MMF)
- Nancy histological index, 351
- Necator americanus (hookworm)
clinical features, 280
differential diagnosis, 280
macroscopic features, 280
microscopic features, 280
- Necrotising enterocolitis (NEC), 110–11
- Neoplasia
anal intraepithelial neoplasia (AIN), 125–6
human papillomavirus (HPV) infection and, 442
LAST classification system, 128
p16 immunohistochemistry, value of, 128
colorectal neoplasia, biopsies and, 10
as complication of inflammatory bowel disease (IBD)
colorectal carcinoma (CRC) (*See* Colorectal carcinoma (CRC))
colorectal dysplasia, 397–8
ileoanal pouch anastomosis (IPAA) cancer, 398
lymphoma, 398
lymphoproliferative disorders, 398
pouch cancer, 398
epithelial neoplasms, 55
lymphoreticular proliferations
lymphoid hyperplasia distinguished, 304–6
lymphoma, 55
lymphoproliferative disorder in IBD, 398
(nodular) lymphoid hyperplasia (NLH), 55
post-transplant lymphoproliferative disorder (PTLD), 55–6
mesenchymal neoplasms in setting of immunosuppression, 56
in rectal cuff, 413
Neutropaenic enterocolitis, 61, 270
- Neutrophils
duodenal mucosa, 151–3
gastric mucosa, 145
ileal mucosa, 249
large intestinal mucosa, 249
oesophageal mucosa, 134
- Nicorandil, anus and, 78
- Nodular lymphoid hyperplasia (NLH), 55
- Non-specific duodenitis, 206–7
- Non-steroidal anti-inflammatory drugs (NSAIDs)
colitis, as mimic of inflammatory bowel disease (IBD), 374–5
duodenal ulceration, 6–7
gastritis, 6, 66, 199–200
ileitis, 68, 300
large intestine and, 73, 75–6, 374–5
oesophagus and, 65
- Non-typhoid salmonella enterica, 266
differential diagnosis, 266
- Norovirus, histology, 294, 295
- NSAIDs. *See* Non-steroidal anti-inflammatory drugs (NSAIDs)
- Oesophageal mucosa, 131–4, 137
anatomy of oesophagus and, 131
epithelium, 137
gastric mucosa distinguished, 137
gastro-oesophageal junction (GOJ), 137–8
general features, 131–4
glycogenic acanthosis, 137
heterotopia, 138–40
inflammatory cells, 134
lamina propria, 134–6, 137
metaplasia, 138–40
muscularis mucosae, 134–6
normal mucosa, summary, 137
papillae, 134–5, 137
submucosa, 136, 137
- Oesophageal squamous dysplasia
general features, 164
histological characterisation, 165–6
molecular characterisation, 165–6
prevalence of, 164
- Oesophageal ulceration, biopsies and, 3, 4
- Oesophagitis
generally, 169
amoebic, 172
bacterial, 171–2
actinomycosis, 172
bartonella, 171–2
role of bacteria in infective oesophagitis, 171
syphilis, 171–2
tuberculosis (TB), 171–2
eosinophilic oesophagitis (EO), 172–5
basic features, 175
biopsies and, 3, 4, 173–4, 175
clinical features, 3, 4
diagnosis, 173–5
pathogenesis, 173
prevalence of, 173
symptoms of, 173
fungal, 172
aspergillus oesophagitis, 172
candida oesophagitis, 172
other fungal infections, 172
helminthic, 172
immunosuppression and, 169
- lichenoid oesophagitis, 175–7
lichen planus oesophagitis, 175–7
- lymphocytic oesophagitis (LO), 175–6
associations, 176
diagnostic approaches, 176
general features, 176
inflammatory bowel disease (IBD) and, 239
protozoal infections, 172
sloughing oesophagitis, 175–7
viral infections, 169–71
cytomegalovirus (CMV) oesophagitis, 169
Herpes simplex virus (HSV) oesophagitis, 169–70
human immunodeficiency virus (HIV) oesophagitis, 170
human papilloma virus (HPV) oesophagitis, 171
- Oesophagus
acute oesophageal necrosis (AEN), 84–5
endoscopic features, 84
general features, 84
histological features, 84
macroscopic, 84
risk factors, 84
acute radiation damage, 38–9
amoebic infection, 172
bacterial oesophagitis, 171–2
actinomycosis, 172
bartonella, 171–2
role of bacteria in infective oesophagitis, 171
syphilis, 171–2
tuberculosis (TB), 171–2
Barrett's oesophagus (BE/BO) (*See* Barrett's oesophagus (BE/BO))
biopsies of, 4
anatomical location of tissue sample, 2
Barrett's oesophagus (BE), 2–3, 4
benign strictures, 3–4
eosinophilic oesophagitis (EO), 3, 4, 173–4, 175
gastro-oesophageal reflux disease (GORD), 3, 4
general points, 4
indications for biopsy, summary, 4
oesophageal ulceration, 3, 4
rarer miscellaneous conditions, 4
chronic radiation damage, 38–9, 40
dermatological conditions and, 25
drug-induced disease, 66
bisphosphonates and, 66
injury patterns, 65
iron-pill associated disease, 65, 66

- NSAIDs and, 65
sloughing oesophagitis, 65–6
- eosinophilic oesophagitis (EO), 172–5
basic features, 175
biopsies and, 3, 4, 173–4, 175
clinical features, 3, 4
diagnosis, 173–5
pathogenesis, 173
prevalence of, 173
symptoms of, 173
- fungal infection, 172
aspergillus oesophagitis, 172
candida oesophagitis, 172
other fungal infections, 172
- heterotopia in, 138–40
- immunosuppression and, 169
- inflammatory bowel disease (IBD) and
lymphocytic oesophagitis (LO), 239
oesophageal granulomas, 239
oesophageal ulcerative colitis (UC), 239
other causes of inflammation that require exclusion, 238, 239
- ischaemia of, 85
- lichenoid oesophagitis, 175–7
- lichen planus oesophagitis, 175–7
- lymphocytic oesophagitis (LO), 175–6
associations, 176
diagnostic approaches, 176
general features, 176
inflammatory bowel disease (IBD) and, 239
- mucosa (*See* Oesophageal mucosa)
- oesophagitis (*See* Oesophagitis)
- protozoal infection, 172
- radiation damage
acute radiation damage, 38–9
atypia, 39
candidiasis in, 39
chronic radiation damage, 38–9, 40
cytology, 39
deeper layers, changes in, 40
diagnosis, 40
mucosal changes, 40
pathogenesis, 39
risk factors for damage, 36
- sloughing oesophagitis, 175–177
- viral infections, 169–71
cytomegalovirus (CMV) oesophagitis, 170
Herpes simplex virus (HSV) oesophagitis, 169–70
- human immunodeficiency virus (HIV) oesophagitis, 170
- human papilloma virus (HPV) oesophagitis, 171
- of Mimics
inflammatory bowel disease (IBD) (*See* Inflammatory bowel disease (IBD)—mimics)
- Oleogranuloma, anal, 444
- Olmesartan
gastritis and, 200
gastrointestinal effects, 70–1
small intestine and, 68, 70–1, 300
- Paediatric conditions
adults compared, 102
allergic conditions
generally, 103
allergic colitis/enterocolitis, 103–4
eosinophilic gastroenteritis (EGE), 104–5
inflammatory bowel disease (IBD)
adults compared, 106, 107, 108
biopsy appearances, 106–7
Crohn's disease, 108–10
histological diagnosis, 106
IBD unclassified (IBDU), 108–9
monogenic IBD-like colitides, 109–10
monogenic/very early onset IBD, 109–10
necrotising enterocolitis (NEC), 110–11
pathogenesis, 106
Pediatric Paris modification of Montreal classification, 110
prevalence of, 105–6
stomach, 240
subgroups according to age, 110
upper GI tract involvement, 237
- paediatric GI mucosa
adult mucosa compared, 102–3
- Pancreas
heterotopic pancreas, 145–7, 212–13
IgG4-related disease (IgG4-RD), pancreas involvement, 21–2
- Paneth cell metaplasia, diagnosis of inflammatory bowel disease (IBD) and, 334–5, 342
- Papillae in oesophageal mucosa, 137
- Parasitic infections. *See also specific infection*
- Amoebiasis, 278, 364–8, 392–4
- Ancylostoma duodenale (hookworm), 280–1
- Ascaris lumbricoides (roundworm), 280
- Chagas disease, 278
as complication of inflammatory bowel disease (IBD)
amoebiasis, 392–4
blastocystis hominis, 394
giardiasis, 393–4
- Cryptosporidium parvum, 278–9
differential diagnosis, 279
- Enterobius vermicularis (pinworm), 279–80
- flagellates
Chagas disease, 278
Cryptosporidium parvum, 278–9
- giardiasis
CVID, association with, 210
histology, 209–10
prevalence of, 209–10
- helminths
Ancylostoma duodenale (hookworm), 280–1
Ascaris lumbricoides (roundworm), 280
clinical features, summary, 280
Enterobius vermicularis (pinworm), 279–80
macroscopic appearances, summary, 280
microscopic features, summary, 280
Necator americanus (hookworm), 280–1
Strongyloidiasis, 281
Trichuris trichiura (whipworm), 280
- immunosuppression and, 54–5
- intestinal amoebiasis, 278, 364–8, 392–4
- Necator americanus (hookworm), 280–1
- parasitic gastritis, 198–9
- schistosomiasis, 281
clinical features, 281
macroscopic pathology, 281
microscopic pathology, 281
- strongyloidiasis, 281
- trematodes, 281
- Trichuris trichiura (whipworm), 280
- PD-1 inhibitor
gastroenterocolitis, 77–8
- Penicillium marneffeii, 277–8
differential diagnosis, 278
- Peptic duodenitis (PD), 206–7, 231
coeliac disease (CD) distinguished, 231
- Peptic ulcer, duodenum, 208
- Peyer's patch, 246–8, 287–8
- Phlegmonous gastritis, 197
- "Pill oesophagitis," 65, 66
- Pilonidal sinus, 443–4
clinical differential diagnosis, 444
histology, 443–4
- Pinworm, 279–80
clinical features, 280
differential diagnosis, 280
macroscopic pathology, 280
microscopic pathology, 280
- Plasma cells
ileal, 246–9
large intestinal, 252–3
- Pneumatosis cystoides intestinalis/
pneumatosis coli, 380–1, 427–8
- Polyarteritis nodosa, 97–8
- Polypoid gastric dysplasia, 122
- Portal hypertensive colopathy, 91–3
- Portal hypertensive duodenopathy, 91–3
- Portal hypertensive enteropathy, 91–3
- Portal hypertensive gastroenteropathy, 91–3
gastric antral vascular ectasia (GAVE) distinguished, 93
general features, 93
histology, summary, 93
polypoid lesions, 93
- Post-transplant lymphoproliferative disorder (PTLD), 55–6
- Pouch cancer, 398
- Pouchitis, 410–15
approach to sampling, 9, 10
causes, 411
classification, 411
histology, 410–15
pouch mucosa
histology, 415
scoring system for histological changes, 412–13
secondary pouchitis, 411
- Primary eosinophilic ileitis/jejunitis, 297, 298
- Proctocolectomy, indications for ileal pouch anal anastomosis (IPAA) following, 410, 411
- Pseudomelanosis duodeni, 213
associations, 213
endoscopy, 213
histology, 213
- Pseudomembranous colitis, 74
- Pseudopyloric metaplasia, small intestine, 291, 292
- Psoriasis, anal, 441
- PTLD (Post-transplant lymphoproliferative disorder), 55–6
- Pyloric gland adenoma, 122

Index

- Pyloric gland metaplasia, small intestine, 291, 292
- Radiation damage
administration of radiation, 30
adverse effects of radiation, overview, 30
anal, 444
appendix, 43
cell death, types of, 31
chemotherapy distinguished, 31
classification of, 32
gastritis and, 41, 67, 200–1
gastrointestinal tract (GI tract) features, 31–3, 38
atypia, 33–4, 38
eosinophils, 32–3
fibrosis, 32–4
inflammation and reactive changes, 38
mucosal changes, 31–3
summary, 38
ulceration, 32–3
vascular changes, 32, 38
histological diagnosis, 34–6
large intestine, 41–2 (*See also* Large intestine)
acute radiation damage, 44–5
atypia, 45
differential diagnosis, 45
epithelium, 45
histology, 45
inflammation, 45
chronic radiation damage, 45–9
atypia, 45–7
crypts, 47
deeper layers, changes in, 47
differential diagnosis, 46–9
epithelium, 47
lamina propria, 45–6, 47
mechanisms, 48–9
mucosal vasculature, 47
submucosa, 47
as mimic of inflammatory bowel disease (IBD), 45, 367
risk factors for damage, 44
oesophagus, 36–40
acute radiation damage, 38–9
atypia, 39
candidiasis in, 39
chronic radiation damage, 38–9, 40
cytology, 39
deeper layers, changes in, 20
diagnosis, 40
mucosal changes, 40
pathogenesis, 39
risk factors for damage, 36
pathogenesis, 30–1
prevalence of, 31
risk factors for radiation damage, 30
GI organ characteristics, 30
patient characteristics, 30
radiotherapy characteristics, 30
risk of subsequent cancer, 50
small intestine, 41–2 (*See also* Small intestine)
acute radiation damage, 42
chronic radiation damage, 42–4
risk factors for damage, 42
stomach, 41, 67, 200–1
acute radiation damage, 40, 41
chronic radiation damage, 40, 41
pathogenesis, 40–1
pathological features, 41
risk factors for damage, 40
selective interventional radiation therapy (SIRT) and, 41, 67–8, 200–1
yttrium-90 microsphere selective internal radiation, 41, 67–8, 200–1
- RCD. *See* Refractory coeliac disease (RCD)
- Reactive gastritis, 190–1
- Recreational drugs, gastritis and, 201
- Rectal cuff, 412–13
- Rectum. *See* Large intestine
- Reflux disease. *See* Gastro-oesophageal reflux disease (GORD)
- Refractory coeliac disease (RCD), 221
RCD 1, 221–2
RCD 2, 222–3
- Reporting inflammatory bowel disease (IBD), 401
assessment of biopsies for inflammatory bowel disease (IBD)
checklist, 404
main histological features, 404
systematic approach, 402–5, 407
useful clinical details, 403
clinicopathological correlation, 401–2
contents of report, 406
grading of histological activity and severity of inflammation, 405–6
guidelines, 401
increase in workload and, 401
necessary clinical information
disease duration, 402
endoscopic findings, 402
useful details when assessing biopsies, 403
optimising biopsy quality, 401, 402
overview, 401
PAID scheme for structure of report, 405, 406–7
proformas, 401
activity, 406
cytomegalovirus (CMV), 406
diagnosis, 406
dysplasia, 406
extent and distribution of disease, 406
malignancy, 406
prognosis, 406
reasons for report, 402–6
structure of report, 403–5
conclusion, 405, 406
description, 405, 406
“PAID” scheme, 405, 406–7
terminology
ambiguous and confusing terms, 406–8
“colitis,” 408
inappropriate use of terms, 409
“indeterminate colitis,” 408–9
“non-specific colitis,” 408
probability terms regarding, 406–8
- Riddell classification of dysplasia in inflammatory bowel disease (IBD), 116
- Rituximab, drug-induced disease of large intestine and, 77
- Robarts histology index (RHI) for inflammatory bowel disease (IBD), 351
- Rotavirus gastroenteritis
duodenitis and, 212
histology, 293–4, 295
- Roundworm, 280
clinical features, 280
differential diagnosis, 280
macroscopic pathology, 280
microscopic pathology, 280
- Russell body gastritis, 191–2
- Salmonella
clinical features, 267
macroscopic features, 267
microscopic features, 267
non-typhoid salmonella enterica, 266
differential diagnosis, 266
salmonella typhi (typhoid fever), 265–6
differential diagnosis, 266
- Sarcoidosis, 13–15
clinical features, 13
course and treatment, 15
diagnosis, 14
differential diagnosis, 14–15
epidemiology, 13
- GI tract involvement, 13–14, 15
liver involvement, 13–14
as mimic of inflammatory bowel disease (IBD), 364–6
- Schistosomiasis, 281
clinical features, 281
macroscopic pathology, 281
microscopic pathology, 281
- Selective interventional radiation therapy (SIRT), 41, 67–8, 200–1
- Serrated lesions, 125
histological features, 123
in inflammatory bowel disease (IBD), 398
terminology, 124
- Sessile serrated adenoma/polyps (SSA/P), 123
- Sevelamer, drug-induced disease of large intestine and, 74–5
- Sexually transmitted proctocolitides, 275
- Chlamydia trachomatis (lymphogranuloma venereum), 273–5, 362–4, 439
clinical features, 275
human immunodeficiency virus (HIV) and, 52, 362–4, 439
microscopic pathology, 275
as mimic of inflammatory bowel disease (IBD), 362–4
clinical features, summary, 275
gonorrhoeal proctitis, 275
microscopic pathology, 275
- Herpes simplex virus (HSV), 261–2
- lymphogranuloma venereum (Chlamydia trachomatis), 273–5, 362–4, 439
clinical features, 275
human immunodeficiency virus (HIV) and, 52, 362–4, 439
microscopic pathology, 275
as mimic of inflammatory bowel disease (IBD), 362–4
macroscopic features, summary, 275
microscopic pathology, summary, 275
organisms, 275
syphilis (*See* Syphilis)
- Shigellosis, 266–8
clinical features, 266–8
differential diagnosis, 267
general features, 266–8
macroscopic features, 267
microscopic features, 267
- SIRT (Selective interventional radiation therapy), 41, 67–8, 200–1

- Skin tags, 435–6
 causes, 436
 granulomas and, 436
 histological features, 436
- Sloughing oesophagitis, 65–6
- Small intestine
 acute radiation damage, 42
 biopsies of
 approach to sampling, 6, 8
 coeliac disease (CD), 7, 8
 duodenal and proximal
 small intestinal,
 general points, 8
 malignancy, ulceration or
 strictures, 7
 chronic radiation damage,
 42–4
 deeper layers, 44
 mucosa, 44
 submucosa, 44
 drug-induced disease
 apoptotic enteropathy, 69
 crystal deposition and, 72
 duodenal intraepithelial
 lymphocytosis, 69
 duodenal villous atrophy,
 68–9
 injury patterns, 68
 ipilimumab, 71–2
 kayexalate, 72
 mycophenolate (MPA) (*See*
 Mycophenolate mofetil
 (MMF))
 olmesartan, 68, 70–1, 300
 specific drugs, 69–72
 ischaemia of, 85
 acute mesenteric ischaemia,
 85–6, 89
 chronic mesenteric
 ischaemia, 85–6, 89
 differential diagnosis, 89–90
 macroscopic features, 86–8
 mesenteric venous
 thrombosis, 89
 microscopic features, 86–8,
 89
 malignancy or strictures,
 biopsies and, 7
 microscopic colitis and, 297,
 321
 radiation damage, 41–2
 acute radiation damage, 42
 chronic radiation damage,
 42–4
 risk factors for damage, 42
 small intestinal bacterial
 overgrowth (SIBO), 230
 strictures
 causes, 304
 general features, 304
 multiple strictures, 304
 villous atrophy, medications
 and, 68–9
- Spirochaetes
 intestinal spirochaetosis,
 273–4
 syphilitic proctitis
 differential diagnosis, 273
- general features, 272–4
 practical considerations,
 273
- Sporadic colorectal dysplasia,
 122–4
- Squamous dysplasia, 117–19
- SSA/P (Sessile serrated adenoma/
 polyps), 123
- Stomach
 acute radiation damage, 40, 41
 anatomy of, 140
 biopsies of
 approach to sampling, 5
 gastric atrophy, 5–6, 7
 gastric polyps, 5, 7
 gastric ulcer, 5, 7
 gastritis, 6
Helicobacter pylori gastritis,
 5, 7
 indications, 7
 iron deficiency anemia
 (IDA), 6, 7
Candida albicans, 198
 chronic radiation damage, 40,
 41
 drug-induced disease, 66, 184,
 199
 aluminum-containing
 antacids or sucralfate,
 67
 chemotherapy and, 31, 68,
 200–1
 colchicine, 67
 doxycycline and, 200
 immunomodulatory agents
 and, 200
 immunosuppressive agents
 and, 200
 infliximab, 200
 injury patterns, 66
 iron pill-associated gastritis,
 66, 199
 mycophenolate mofetil
 (MMF) and, 56–7, 200
 non-steroid anti-
 inflammatory drugs
 (NSAIDs) and,
 199–200
 OsmoPrep, 67
 radiation and, 40, 41, 200–1
 reactive/chemical
 gastropathy, 66–7
 recreational drugs and, 201
 specific drugs, 67–8
 tablet or crystal deposition
 and, 66, 199
 ulceration, 67
 yttrium-90 microsphere
 selective internal
 radiation, 41, 67–8,
 200–1
 heterotopic pancreas in, 145–7
 inflammatory bowel disease
 (IBD), 107–8, 240
 in children, 107–8, 240
 focally enhanced gastritis
 (FEG), 107–8, 240, 241
 gastric granulomas, 240–1
 prevalence of, 239–40
 ulcerative colitis (UC), 241
 ischaemia of, 85
 mucosa (*See* Gastric mucosa)
 pancreatic heterotopia, 145–7
 radiation damage
 acute radiation damage, 40,
 41
 chronic radiation damage,
 40, 41
 general features, 41
 pathogenesis, 40–1
 risk factors for damage, 40
 selective interventional
 radiation therapy
 (SIRT) and, 41, 67–8,
 200–1
 yttrium-90 microsphere
 selective internal
 radiation, 67–8, 200–1,
 404
- Strongyloides intestinalis, 281
 clinical features, summary, 281
 duodenitis and, 210
 general features, 281
 macroscopic features,
 summary, 281
 microscopic features,
 summary, 281
- Submucosa
 duodenum, 152, 153–4
 ileum, 250
 large intestine, 256–7
 chronic radiation damage
 and, 47
 in oesophageal mucosa, 136,
 137
 small intestine, chronic
 radiation damage and, 44
- Sydney system for classifying
 gastritis, 180–1
 updated Sydney system, 181
- Syphilis
 anal syphilis, 440
 confirmation of diagnosis,
 440
 histological features, 440
 incidence, 440
 lesions, 440
 practical considerations,
 440
 colorectal/rectal syphilis, 275,
 362–4
 differential diagnosis, 273
 gastritis and, 199
 general features, 272–4
 as mimic of inflammatory
 bowel disease (IBD),
 362–4
 practical considerations, 273
- Systemic disease, gastrointestinal
 involvement, 13. *See*
also specific disease
- Takayasu arteritis, 97–8
 TB. *See* Tuberculosis (TB)
- Terminal ileum, biopsies of, 8, 10
- Transplantation
 acute graft-versus-host disease
 (GvHD) and, 57–9, 60
 biopsies, clinical data needed
 for optimal assessment,
 62
 bone marrow transplants, 60
 chronic graft-versus-host
 disease (GvHD) and,
 59–60
 cord colitis syndrome and, 60
 liver transplants, 60
 miscellaneous transplant-
 related gastrointestinal
 diseases, 60–1
 renal transplantation,
 relationship with
 inflammatory bowel
 disease (IBD), 353
 ulceration of upper GI tract,
 60–1
- Trematodes, 281
- Trichuris trichiura* (whipworm),
 280
- Tropical sprue (TS), 230–1
 TS (Tropical sprue), 230–1
- Tuberculosis (TB), 271–2
 differential diagnosis, 272
 duodenitis and, 212
 gastritis and, 199
 granulomas in, 366
 ileal, 298
 intestinal, 271–2
 as complication of
 inflammatory bowel
 disease (IBD), 394
 Crohn's disease,
 comparison of
 granulomas in, 366
 Crohn's disease, features
 resembling, 366
 as mimic of inflammatory
 bowel disease (IBD),
 362–6
 oesophagitis and, 171–2
- Typhlitis, 61, 270
- Typhoid fever, 265–6
 differential diagnosis, 266
- UC. *See* Ulcerative colitis (UC)
- Ulcer-associated cell lineage,
 small intestine, 291,
 292
- Ulceration
 duodenal ulcer, 208
 biopsies and, 8
 clinical features, 6–7
 malignant duodenal
 ulceration or strictures,
 8
 gastric ulcer, biopsies and, 5, 7
 oesophageal ulceration,
 biopsies and, 3, 4
 peptic ulcer of duodenum, 208
 radiation damage and, 32–3
 small intestinal ulcer, causes
 of, 303
 stomach, drug-induced disease
 of, 67

Index

- Ulceration (cont.)
ulcerative colitis (UC) (*See* Ulcerative colitis (UC))
ulcerative jejunitis (UJ), 223
- Ulcerative colitis (UC)
clinical features, 325–6
diversion proctocolitis (DPC) and, 361
diverticular colitis and, 357–9, 421, 424
features favouring ulcerative colitis (UC) over Crohn's disease, 337–9, 343
activity, 339
crypt architectural changes, 337–43
crypt atrophy, 337–43
gradient of changes between sites, 339–40
ileal inflammation, absence of, 339
mucin depletion, 337
reliable distinguishing features, 337–9
summary, 343
villiform mucosal surface, 337–43
- ileal pouch anal anastomosis (IPAA) in, 413–14
- ileitis in
general features, 301
histology, 301
- subclassification of
inflammatory bowel disease (IBD) as, 347
- upper GI tract involvement, 236
distinguishing from Crohn's disease, 237
gastric, 241
implications of new upper GI disease for existing diagnosis of UC, 243
oesophageal, 239
paediatric, 107–8
- Ulcerative jejunitis, 223
- Upper gastrointestinal tract, drug-induced disease, 65
- Vascular abnormalities
angiodysplasia, 90–1
arteriovenous malformation (AVM), 94, 95
Dieulafoy's lesion, 93–4, 95
Ehlers-Danlos syndrome, 95–6
gastric antral vascular ectasia (GAVE), 90–1
clinical features, 93
histology of, 93
portal hypertensive gastroenteropathy distinguished, 93
hereditary haemorrhagic telangiectasia, 94–5
idiopathic myointimal hyperplasia of mesenteric veins (IMHMV), 94, 95
main features of vascular malformations, 95
portal hypertensive colopathy, 91–3
portal hypertensive duodenopathy, 91–3
portal hypertensive enteropathy, 91–3
portal hypertensive gastroenteropathy, 91–3
gastric antral vascular ectasia (GAVE) distinguished, 93
general features, 93
histology, summary, 93
polypoid lesions, 93
systemic diseases affecting gastrointestinal vasculature
Ehlers-Danlos syndrome, 95–6
hereditary haemorrhagic telangiectasia, 94–5
vasculitides, 96–8
clinical features, 97–8
pathological features, 97–8
- Vibrio cholerae, 263
- Viral infections. *See also specific infection*
adenovirus (*See* Adenovirus)
cytomegalovirus (CMV) (*See* Cytomegalovirus (CMV))
Herpes simplex virus (HSV) generally, 197
anogenital, 439
gastritis, 197
oesophagitis, 169–70
proctitis
clinical features, 263
differential diagnosis, 263
histological features, 261–2, 263
macroscopic pathology, 263
risk factors, 261–2
radiation change, mimicking, 33–4
- Herpes varicella zoster, 197
human immunodeficiency virus (HIV) (*See* Human immunodeficiency virus (HIV))
immunosuppression and, 53–4
adenovirus, 53
cytomegalovirus (CMV), 53
in lower GI tract, 260–2 (*See also specific infection*)
rotavirus
histology, 295
viral duodenitis and, 212
viral duodenitis, 212
cytomegalovirus (CMV) duodenitis, 212
rotavirus, 212
viral gastritis, 197–8
cytomegalovirus (CMV), 197
Epstein-Barr virus (EBV), 197–8
Herpes varicella zoster, 197
viral gastroenteritis, 293–4, 295
adenovirus, 294, 295
clinical features, 260–2
differential diagnosis, 261
general features, 260–2
histology, 53, 260–2, 294, 295
immunosuppression and, 53
practical considerations, 261
norovirus, 294, 295
other viruses, 295
pathological features, summary, 262
rotavirus, 212, 293–4, 295
viral oesophagitis, 169–71
cytomegalovirus (CMV), 170
Herpes simplex virus (HSV) oesophagitis, 169–70
human immunodeficiency virus (HIV) oesophagitis, 169
human papilloma virus (HPV) oesophagitis, 171
- Weight loss surgery, Helicobacter pylori gastritis and, 196–7
- Whipple's disease, 210–12
gastric, 184, 189
- general features, summary, 212
histology, summary, 212, 287, 295
intestinal, 212, 272
common variable immune deficiency as mimic of, 376–7
oesophageal, 172
- Whipworm, 280
clinical features, 280
differential diagnosis, 280
macroscopic pathology, 280
microscopic pathology, 280
- Wiskott-Aldrich syndrome
immunosuppression and, 61
as mimic of inflammatory bowel disease (IBD), 379
- Xanthogranulomatous gastritis, 192
- X-linked agammaglobulinaemia
colorectal bacterial overgrowth in, 52
as mimic of inflammatory bowel disease (IBD), 377
risk of neoplasia in, 55
- Yeast, 277–8
Candida albicans
gastric, 198
in ileoanal pouch anastomosis, 411
oesophageal, 172
in oesophageal radiation damage, 39
small intestinal, 295
histoplasmosis, 277
differential diagnosis, 277
Penicillium marneffeii, 277–8
differential diagnosis, 278
- Yersinia. *See* Yersiniosis
- Yersiniosis, 264–5, 295, 364
clinical features, 265
differential diagnosis, 265
macroscopic pathology, 265
microscopic pathology, 265, 294
as mimic of inflammatory bowel disease (IBD), 364
- Yttrium-90 microsphere
selective internal radiation, disease of stomach and, 41, 67–8, 200–1